Home The Word Brain My Amedeo FAQ Privacy About   


Hanzi Hunter — ultra-fast Hanzi study

All 1,152 characters from the aioLingua manual

AbstractAboutThe 20 audio files

← aioLingua Chinese Online

← Chinese aioLingua PDF


  Parkinson's Disease

  Free Subscription


Articles published in Mov Disord

Retrieve available abstracts of 508 articles:
HTML format



Single Articles


    November 2025
  1. CAMACHO M, Greenland JC, Peattie ARD, Spindler LRB, et al
    Constipation Is Linked to Neuroinflammation in Early Parkinson's Disease.
    Mov Disord. 2025 Nov 13. doi: 10.1002/mds.70102.
    PubMed     Abstract available


  2. PATEL B, Camacho M, Evans JR, Breen DP, et al
    The rs6971 TSPO Polymorphism Does Not Influence Disease Presentation or Progression in Parkinson's Disease rs6971 TSPO Polymorphism in PD.
    Mov Disord. 2025 Nov 3. doi: 10.1002/mds.70105.
    PubMed    


  3. HIRSCHWALD J, Warnecke T
    Reply to "Comments on 'Measuring What Matters in Parkinson's Disease Research and Dysphagia: The Need for Core Outcome Sets'".
    Mov Disord. 2025 Nov 1. doi: 10.1002/mds.70112.
    PubMed    


  4. XIE T, Bloom L, McCracken E
    Comments on "Measuring What Matters in Parkinson's Disease Research and Dysphagia: The Need for Core Outcome Sets".
    Mov Disord. 2025 Nov 1. doi: 10.1002/mds.70113.
    PubMed    


  5. VIRAMETEEKUL S, Shin C, Hirczy SS, Sarva H, et al
    Assessing Digital Health Technologies for Outcome Measurement in Parkinson's Disease Drug Trials: A Systematic Review.
    Mov Disord. 2025 Nov 1. doi: 10.1002/mds.70097.
    PubMed     Abstract available


    October 2025
  6. RACHAO A, Silva A, Prada L, Pona-Ferreira J, et al
    Advertising to Healthcare Professionals: Insights from Parkinson's Disease in the Movement Disorders Journal.
    Mov Disord. 2025 Oct 30. doi: 10.1002/mds.70108.
    PubMed    


  7. DE BIE RMA, Katzenschlager R, Bruno V, Sampaio C, et al
    Reply: "Treatment Options for Motor Fluctuations in Parkinson's Disease".
    Mov Disord. 2025 Oct 28. doi: 10.1002/mds.70109.
    PubMed    


  8. HOGLINGER G, Lingor P, Hollerhage M, Trenkwalder C, et al
    Treatment Options for Motor Fluctuations in Parkinson's Disease.
    Mov Disord. 2025 Oct 28. doi: 10.1002/mds.70107.
    PubMed    


  9. ALAM MS, Yu L, Stebbins GT, Mestre TA, et al
    Longitudinal Evaluation of an Abbreviated Patient-Reported Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) for Predicting Dopaminergic Therapy Initiation in Early Parkinson's Disease.
    Mov Disord. 2025 Oct 27. doi: 10.1002/mds.70096.
    PubMed     Abstract available


  10. HU Z, Wan JJ, Yan QQ, Fan Y, et al
    Further Investigation of Catechol-O-Methyltransferase Gene and Parkinson's Disease Susceptibility in the UK Biobank Cohort.
    Mov Disord. 2025 Oct 27. doi: 10.1002/mds.70098.
    PubMed    


  11. LIN YY, Raies N, Grippe T, Gunraj CA, et al
    Transcranial Ultrasound Stimulation of Internal Globus Pallidus Region and Motor Cortex in Parkinson's Disease.
    Mov Disord. 2025 Oct 23. doi: 10.1002/mds.70095.
    PubMed     Abstract available


  12. LETA V, Zinzalias P, Batzu L, Mandal G, et al
    Effects of a Four-Strain Probiotic on Gut Microbiota, Inflammation, and Symptoms in Parkinson's Disease: A Randomized Clinical Trial.
    Mov Disord. 2025 Oct 23. doi: 10.1002/mds.70047.
    PubMed     Abstract available


  13. WU Z, Zhu S, Hong R, Zhang Z, et al
    A Network Centered on the Visual-Motor Cortex Is Critically Involved in Postural Abnormality in Parkinson's Disease.
    Mov Disord. 2025 Oct 23. doi: 10.1002/mds.70088.
    PubMed     Abstract available


  14. KOCH MW, Kalia LV, Sarna J, Aquino C, et al
    Feasibility of Simon Two-Stage Futility Trials in People with Early, Symptomatically Treated Parkinson's Disease.
    Mov Disord. 2025 Oct 20. doi: 10.1002/mds.70090.
    PubMed     Abstract available


  15. PAPARELLA G, De Riggi M, Cannavacciuolo A, Birreci D, et al
    Analyzing the 'Bradykinesia Complex' in Parkinson's Disease.
    Mov Disord. 2025 Oct 17. doi: 10.1002/mds.70082.
    PubMed     Abstract available


  16. KLEINZ T, Cavallieri F, Borsche M, Toschi G, et al
    RAB32-Linked Parkinson's Disease: Deep Phenotyping, MDSGene Literature Review, and Application of SynNeurGe Criteria.
    Mov Disord. 2025 Oct 17. doi: 10.1002/mds.70037.
    PubMed     Abstract available


  17. LANGE LM, Fang ZH, Screven L, Tan AH, et al
    Rare but Relevant? Assessing Variants in Dystonia-Linked Genes in Parkinson's Disease.
    Mov Disord. 2025 Oct 11. doi: 10.1002/mds.70073.
    PubMed     Abstract available


  18. HU Z, Yan QQ, Wan JJ, Fan Y, et al
    Association of Non-Coding Repeat Expansions with Parkinson's Disease Risk: Evidence from a UK Biobank-Based Whole-Genome Sequencing Study.
    Mov Disord. 2025 Oct 11. doi: 10.1002/mds.70081.
    PubMed     Abstract available


  19. RICCIARDI L, Fanciulli A, Cucinotta FP, Ishihara B, et al
    Sympathetic Shift and Insular Alteration: Unravelling the Link Between Anxiety and Heart Rate Variability in Parkinson's Disease.
    Mov Disord. 2025 Oct 7. doi: 10.1002/mds.70069.
    PubMed     Abstract available


  20. ABDI-SARGEZEH B, Shirani S, Sharma A, Liu T, et al
    Prediction of Pathological Subthalamic Nucleus Beta Burst Occurrence in Parkinson's Disease.
    Mov Disord. 2025 Oct 3. doi: 10.1002/mds.70076.
    PubMed     Abstract available


  21. SADABAD FE, Volpi T, Honhar P, Tinaz S, et al
    Measuring Dopamine Transporter Availability and Synaptic Density in Parkinson's Disease: A Dual-Tracer Positron Emission Tomography Imaging Study.
    Mov Disord. 2025 Oct 3. doi: 10.1002/mds.70041.
    PubMed     Abstract available



  22. 2025 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2025;40 Suppl 1:S1-S60.
    PubMed    



  23. 2025 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2025;40 Suppl 1:S413-S1072.
    PubMed    



  24. 2025 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2025;40 Suppl 1:S229-S245.
    PubMed    



  25. 2025 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2025;40 Suppl 1:S382-S412.
    PubMed    



  26. 2025 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2025;40 Suppl 1:S78-S162.
    PubMed    



  27. 2025 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2025;40 Suppl 1:S271-S381.
    PubMed    



  28. 2025 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2025;40 Suppl 1:S163-S228.
    PubMed    



  29. 2025 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2025;40 Suppl 1:S61-S77.
    PubMed    



  30. 2025 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2025;40 Suppl 1:S246-S270.
    PubMed    


  31. GRAYBIEL AM
    Surprises From the Basal Ganglia: Stop and Go Have New Meaning.
    Mov Disord. 2025;40:2077-2082.
    PubMed     Abstract available


  32. ZHANG D, Luo L, Li L, Yao J, et al
    Glymphatic Dysfunction in Non-Manifesting Carriers of LRRK2 and GBA Pathogenic Variants.
    Mov Disord. 2025;40:2189-2198.
    PubMed     Abstract available


    September 2025
  33. KISHORE A, Borgohain R, Puthenveedu DK, Rajan R, et al
    Reply to: "Early Indian Age at Onset of Parkinson's: A Case for a Gene-Environment Lens".
    Mov Disord. 2025 Sep 30. doi: 10.1002/mds.70053.
    PubMed    


  34. ONDER H, Pekgoz Z, Oztekin MF
    Early Indian Age at Onset of Parkinson's: A Case for a Gene-Environment Lens.
    Mov Disord. 2025 Sep 30. doi: 10.1002/mds.70055.
    PubMed    


  35. DE NEELING MGJ, Geraats S, Swinnen BEKS, Stam MJ, et al
    Temporal Dynamics of Beta Power Related to the Stun Effect in Parkinson's Disease Patients after Deep Brain Stimulation Surgery.
    Mov Disord. 2025 Sep 30. doi: 10.1002/mds.70042.
    PubMed     Abstract available


  36. VARANDA S, Carneiro G, Pinho J
    Public Healthcare for People with Parkinson's Disease in Portugal: Rising to the Challenge.
    Mov Disord. 2025 Sep 29. doi: 10.1002/mds.70078.
    PubMed    


  37. FAN Y, Hu Z, Yan QQ, Wan JJ, et al
    Reply to "Prevalence of NOTCH2NLC and FMR1 Repeat Expansions in Atypical Parkinsonism Compared to Asymptomatic Elderly Individuals".
    Mov Disord. 2025 Sep 24. doi: 10.1002/mds.70060.
    PubMed    


  38. MARTIN-BORNEZ M, Shar N, Nour MA, Murphy D, et al
    Does COMT Play a Role in Parkinson's Disease Susceptibility across Diverse Ancestral Populations?
    Mov Disord. 2025 Sep 23. doi: 10.1002/mds.70040.
    PubMed     Abstract available


  39. ZHAO Y, Pan H, Wang Y, Chen J, et al
    Expanding the Autosomal Recessive Gene Spectrum of Parkinson's Disease: A Study within the CPD10KGP.
    Mov Disord. 2025 Sep 17. doi: 10.1002/mds.70039.
    PubMed     Abstract available


  40. TAY YW, Ooi JCE, Lim SY, Chia YK, et al
    Very High Frequency of Early-Onset Parkinson's Disease and PRKN Mutations among Indigenous Patients in Sabah, Malaysia.
    Mov Disord. 2025 Sep 15. doi: 10.1002/mds.70015.
    PubMed     Abstract available


  41. VIDENOVIC A, Coffey CS, Klerman EB, Cudkowicz M, et al
    ENLITE PD: A Randomized Clinical Trial of Light Therapy for Impaired Sleep in Parkinson's Disease.
    Mov Disord. 2025 Sep 6. doi: 10.1002/mds.70009.
    PubMed     Abstract available


  42. ZHAO H, Hao S, Zhang P, He S, et al
    Cortical and Corticomuscular Beta-Gamma Phase-Amplitude Coupling During Different Locomotion States and the Effects of Levodopa in Parkinson's Disease.
    Mov Disord. 2025 Sep 6. doi: 10.1002/mds.70031.
    PubMed     Abstract available


  43. AL-AZZANI M, Weber S, Ramalingam N, Ramon M, et al
    A Novel alpha-Synuclein K58N Missense Variant in a Patient with Parkinson's Disease.
    Mov Disord. 2025 Sep 4. doi: 10.1002/mds.70030.
    PubMed     Abstract available


  44. DE MORAES ALVES AL, da Silva Simoes J, Trajano da Silva LR, Neto AF, et al
    Transcutaneous Spinal Magnetic Stimulation Affects Subthalamic Activity in Parkinson's Disease.
    Mov Disord. 2025 Sep 3. doi: 10.1002/mds.70035.
    PubMed    


  45. SCHIESS MC, Suescun J, Martinez-Lemus JD, Green C, et al
    Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells for Parkinson's Disease: A Randomized Trial.
    Mov Disord. 2025 Sep 1. doi: 10.1002/mds.70028.
    PubMed     Abstract available


  46. HAQ IU, Simonyan K, Napoli E, Ozelius LJ, et al
    Structural Alterations in the Gray Matter Volume in Rapid-Onset Dystonia-Parkinsonism.
    Mov Disord. 2025 Sep 1. doi: 10.1002/mds.30320.
    PubMed     Abstract available


  47. COHEN JS, Radhakrishnan H, Olm CA, Das SR, et al
    Microstructural Changes in the Tuberal Hypothalamus Correlate with Daytime Sleepiness in Lewy Body Disorders.
    Mov Disord. 2025;40:1919-1929.
    PubMed     Abstract available


  48. WONG JK, Horn A, Middlebrooks EH, Burns MR, et al
    A Convergent Pathway for Stimulation-Induced Dyskinesia Following Deep Brain Stimulation.
    Mov Disord. 2025;40:1901-1907.
    PubMed     Abstract available


    August 2025
  49. FANT A, Trova S, Monfrini E, Treves G, et al
    Compound Heterozygous Structural Variants in Cases with Unsolved PRKN-Associated Parkinson's Disease.
    Mov Disord. 2025 Aug 30. doi: 10.1002/mds.70027.
    PubMed     Abstract available


  50. KERSEBAUM D, Lassen J, Forstenpointner J, Sendel M, et al
    Electrophysiological Evidence for Impaired Central Pain Modulation in Parkinson's Disease.
    Mov Disord. 2025 Aug 23. doi: 10.1002/mds.70004.
    PubMed     Abstract available


  51. ROSSI M, Farris CM, Baiardi S, Giannini G, et al
    Comparison of Two alpha-Synuclein Seed Amplification Assays for Discrimination of Parkinson Disease and Atypical Parkinsonism.
    Mov Disord. 2025 Aug 20. doi: 10.1002/mds.70017.
    PubMed     Abstract available


  52. YIN KF, Gu XJ, Yu JM, Su WM, et al
    Epigenetic Mediating Mechanisms in Parkinson's Disease: The Impact of Educational Attainment on SETD1A Expression.
    Mov Disord. 2025 Aug 19. doi: 10.1002/mds.70010.
    PubMed     Abstract available


  53. IGNATAVICIUS A, Churchill L, Anderson J, Konuri A, et al
    Combined Dysfunction of the Amygdala and Nucleus Basalis Underlies Visual Hallucinations in Parkinson's Disease.
    Mov Disord. 2025 Aug 13. doi: 10.1002/mds.70011.
    PubMed     Abstract available


  54. FLORES-TORRES MH, Peng X, Jeanfavre S, Clish C, et al
    Plasma Metabolomics Profiles in Prodromal and Clinical Parkinson's Disease.
    Mov Disord. 2025 Aug 13. doi: 10.1002/mds.30308.
    PubMed     Abstract available


  55. FIUME S, Molinari F, Vai B, Poletti S, et al
    Prognostic and Biological Roles of Parkinson's Disease-Associated Genes in Cancer.
    Mov Disord. 2025 Aug 12. doi: 10.1002/mds.30321.
    PubMed     Abstract available


  56. FERRANTE FJ, Escobar Grisales D, Lopez MF, Lopes da Cunha P, et al
    Cognitive Phenotyping of Parkinson's Disease Patients Via Digital Analysis of Spoken Word Properties.
    Mov Disord. 2025 Aug 12. doi: 10.1002/mds.70005.
    PubMed     Abstract available


  57. CLARKE N, Thornton P, Reader V, Lindsay N, et al
    Anti-Neuroinflammatory and Anti-Inflammatory Effects of the NLRP3 Inhibitor NT-0796 in Subjects with Parkinson's Disease.
    Mov Disord. 2025 Aug 12. doi: 10.1002/mds.30307.
    PubMed     Abstract available


  58. KRAUSS J, Upadhyay N, Purrer V, Borger V, et al
    Probabilistic Mapping of Magnetic Resonance-Guided Focused Ultrasound (MRgFUS) Thalamotomy Targets in Essential Tremor and Tremor-Dominant Parkinson's Disease: Insights from a German Cohort.
    Mov Disord. 2025 Aug 8. doi: 10.1002/mds.70003.
    PubMed     Abstract available


  59. ZARKALI A, Thomas G, Paterson R, Hannaway N, et al
    Impaired Glymphatic Clearance, Measured Using Diffusion Tensor Image Analysis Along the Perivascular Space (DTI-ALPS), is Linked to Poor Cognitive Outcomes in Parkinson's Disease.
    Mov Disord. 2025 Aug 7. doi: 10.1002/mds.30325.
    PubMed     Abstract available


  60. LOO RTJ, Pavelka L, Mangone G, Khoury F, et al
    Interpretable Machine Learning for Cross-Cohort Prediction of Motor Fluctuations in Parkinson's Disease.
    Mov Disord. 2025;40:1604-1617.
    PubMed     Abstract available


  61. VARGAS GONZALEZ E, Yang Z, Dodet P, Leu-Semenescu S, et al
    Rapid Eye Movements (REMs) during Non-REM Sleep as a Marker of Alpha-Synucleinopathies.
    Mov Disord. 2025;40:1595-1603.
    PubMed     Abstract available


  62. BRINKERHOFF S, Nakhmani A, Varghese A, Gordon C, et al
    Paired Deep Brain Stimuli Elicit Short-Term Facilitation in Globus Pallidus Interna and Subthalamic Nucleus.
    Mov Disord. 2025;40:1636-1647.
    PubMed     Abstract available


    July 2025
  63. KISHORE A, Borgohain R, Puthenveedu DK, Rajan R, et al
    Demographic and Clinical Profiles of Parkinson's Disease in India: Observations from a Nation-Wide Multicenter Study.
    Mov Disord. 2025 Jul 31. doi: 10.1002/mds.30310.
    PubMed     Abstract available


  64. PRATUSEVICIUTE N, Lis P, Weber S, Gruchy N, et al
    Functional and Structural Characterization of LRRK2 p.V1447L in Parkinson's Disease.
    Mov Disord. 2025 Jul 30. doi: 10.1002/mds.30284.
    PubMed     Abstract available


  65. MATTIA GM, Chougar L, Foubert-Samier A, Meissner WG, et al
    Deep Learning to Differentiate Parkinsonian Syndromes Using Multimodal Magnetic Resonance Imaging: A Proof-of-Concept Study.
    Mov Disord. 2025 Jul 24. doi: 10.1002/mds.30300.
    PubMed     Abstract available


  66. ANGELINI L, van den Berg K, Dirkx M, Bologna M, et al
    Reliability of Neuroimaging and Neurophysiological Tremor Features in Parkinson's Disease.
    Mov Disord. 2025 Jul 21. doi: 10.1002/mds.30299.
    PubMed     Abstract available


  67. VALLI A, Scheperjans F
    Subacute Painful Axonal Polyneuropathy Associated with Foslevodopa/Foscarbidopa Subcutaneous Infusion in Advanced Parkinson's Disease.
    Mov Disord. 2025 Jul 18. doi: 10.1002/mds.30297.
    PubMed    


  68. SWINNEN BEKS, Hoy CW, Little SJ
    Towards Adaptive Deep Brain Stimulation for Non-Motor Symptoms in Parkinson's Disease?
    Mov Disord. 2025 Jul 18. doi: 10.1002/mds.30212.
    PubMed     Abstract available


  69. BIUNDO R, Bezdicek O, Cammisuli DM, Cholerton B, et al
    Attention/Working Memory and Executive Function in Parkinson's Disease: Review, Critique, and Recommendations.
    Mov Disord. 2025 Jul 18. doi: 10.1002/mds.30293.
    PubMed     Abstract available


  70. IKEZAWA J, Yokochi F, Yamaguchi T, Abe K, et al
    Bilateral Effects of Unilateral Pallidothalamic Tractotomy Using Focused Ultrasound in Parkinson's Disease.
    Mov Disord. 2025 Jul 17. doi: 10.1002/mds.30281.
    PubMed     Abstract available


  71. WEINTRAUB D, Schoen I
    The FDA Has Ended Required Blood Monitoring for Clozapine Use-Will This Impact the Management of Parkinson's Disease Psychosis?
    Mov Disord. 2025 Jul 15. doi: 10.1002/mds.30295.
    PubMed    


  72. CHEN PS, Liu YL, Chiang PT, Tsai HH, et al
    Prevalence of NOTCH2NLC and FMR1 Repeat Expansions in Atypical Parkinsonism Compared to Asymptomatic Elderly Individuals.
    Mov Disord. 2025 Jul 15. doi: 10.1002/mds.30290.
    PubMed     Abstract available


  73. DAI Y, Bi M, Jiao Q, Du X, et al
    Deciphering the Janus-Faced Nature of the Apolipoprotein Superfamily in Parkinsonian Neurodegeneration: Molecular Crosstalk Between the Astroglial Secretome and Neuronal Homeostasis.
    Mov Disord. 2025 Jul 14. doi: 10.1002/mds.30294.
    PubMed     Abstract available


  74. KUNG PJ, Tsai YT, Yu RL, Lin-Wang HH, et al
    Elevated Levels of Extracellular Vesicle-Associated TAOK1 in Plasma: A Diagnostic Marker for Cognitive Decline in Parkinson's Disease Dementia and Alzheimer's Disease.
    Mov Disord. 2025 Jul 11. doi: 10.1002/mds.30287.
    PubMed    


  75. MOURADIAN MM, Stoessl AJ, Lang AE
    Disease-Modifying Trials in Treated Parkinson's Disease: "Stable Treated" Does Not Equate with Biological Stability.
    Mov Disord. 2025 Jul 10. doi: 10.1002/mds.30259.
    PubMed     Abstract available


  76. OOI JCE, Tay YW, Tan AH, Lin CH, et al
    Evaluation of a Mitochondrial Polygenic Score for Parkinson's Disease Across Ancestries.
    Mov Disord. 2025 Jul 9. doi: 10.1002/mds.30285.
    PubMed    


  77. REIS CARNEIRO D, Morgadinho A, Araujo R
    The Emergence of a New Healthcare Paradigm for People with Parkinson's Disease in Portugal: Brief Notes on Public and Private Healthcare Systems.
    Mov Disord. 2025 Jul 9. doi: 10.1002/mds.30292.
    PubMed    


  78. TOTSUNE T, Baba T, Hasegawa T, Takeda A, et al
    Unraveling the Gut-Heart Axis: Missing Links in the Brain-First Versus Body-First Hypothesis of Parkinson's Disease.
    Mov Disord. 2025 Jul 7. doi: 10.1002/mds.30268.
    PubMed    


  79. BORGHAMMER P, Van Den Berge N, Skjaerbaek C, Horsager J, et al
    Trusting Your Gut When it Comes to the Origin of Parkinson's Disease.
    Mov Disord. 2025 Jul 7. doi: 10.1002/mds.30288.
    PubMed    


  80. XU X, Guo Y, Xiong Y, Min Z, et al
    Substantia Nigra Elasticity Measurement Using Transcranial Shear Wave Elastography: A Potential Biomarker for Parkinson's Disease.
    Mov Disord. 2025 Jul 5. doi: 10.1002/mds.30289.
    PubMed     Abstract available


  81. BOURQUE M, Morissette M, Bortolato M, Frau R, et al
    Pregnenolone Reduces L-Dopa-Induced Dyskinesias in Female Parkinsonian Monkeys.
    Mov Disord. 2025 Jul 5. doi: 10.1002/mds.30280.
    PubMed     Abstract available


  82. LI C, Ou R, Hou Y, Wei Q, et al
    Validation of Genome-Wide Association Study (GWAS)-Identified Risk Loci for Parkinson's Disease in the Chinese Population.
    Mov Disord. 2025 Jul 3. doi: 10.1002/mds.30291.
    PubMed    


  83. LI C, Ou R, Hou Y, Wei Q, et al
    GBA1 Haplotypes and Age at Onset of Parkinson's Disease in the Asian Population.
    Mov Disord. 2025 Jul 2. doi: 10.1002/mds.30283.
    PubMed    


  84. SIMUNI T, Gochanour C, Nair AR, Brumm MC, et al
    Neuronal alpha-Synuclein Disease Stage Progression over 5 Years.
    Mov Disord. 2025;40:1318-1330.
    PubMed     Abstract available


  85. GONZALEZ-ROBLES C, Athauda D, Barber TR, Barker RA, et al
    Treatment Selection and Prioritization for the EJS ACT-PD MAMS Trial Platform.
    Mov Disord. 2025;40:1307-1317.
    PubMed     Abstract available


  86. KAWABATA K, Krismer F, Ito M, Hara K, et al
    Trajectories of Pontine Volume in Patients with Multiple System Atrophy.
    Mov Disord. 2025;40:1369-1378.
    PubMed     Abstract available


  87. MIMMI S, Parrotta EI, Tolomeo AM, Maisano D, et al
    Neuronally-Derived Extracellular Vesicles Transforming Growth Factor Beta-1 Levels in Progressive Supranuclear Palsy.
    Mov Disord. 2025;40:1420-1426.
    PubMed     Abstract available


    June 2025
  88. ANJUM T, Raethjen J, Ding H, Koirala N, et al
    Central Pathophysiology and Brain Network Changes Related to Camptocormia in Parkinson's Disease.
    Mov Disord. 2025 Jun 29. doi: 10.1002/mds.30278.
    PubMed     Abstract available


  89. ESPAY AJ, Cardoso F, Frucht SJ, Imarisio A, et al
    Refutation of the alphaSyn-SAA-Based Staging for Parkinson's Progression (Neuronal alpha-Synuclein Disease-Integrated Staging System [NSD-ISS]).
    Mov Disord. 2025 Jun 27. doi: 10.1002/mds.30269.
    PubMed    


  90. SIMUNI T, Chahine LM, Poston KL, Kopil CM, et al
    Reply to: "Refutation of the alphaSyn-SAA-Based Staging for Parkinson's Progression (Neuronal alpha-Synuclein Disease-Integrated Staging System [NSD-ISS])".
    Mov Disord. 2025 Jun 27. doi: 10.1002/mds.30272.
    PubMed    


  91. HERTZ E, Rytel K, Perez G, Hao Y, et al
    Evaluation of Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons from Siblings with Gaucher Disease Discordant for Parkinsonism.
    Mov Disord. 2025 Jun 26. doi: 10.1002/mds.30273.
    PubMed     Abstract available


  92. HUH YE, Jang B, Jung SH, Kim D, et al
    Protective Effects of Genetic Proxies of Cognitive Reserve in Parkinson's Disease: A Longitudinal Multi-Cohort Study.
    Mov Disord. 2025 Jun 25. doi: 10.1002/mds.30276.
    PubMed     Abstract available


  93. PASCHEN S, Natera-Villalba E, Rodriguez-Rojas R, Del Alamo M, et al
    Lesioning the Subthalamic Nucleus Using Magnetic Resonance Imaging-Guided Focused Ultrasound in Parkinson's Disease: Subthalamotomy Effectively Describes the Procedure.
    Mov Disord. 2025 Jun 23. doi: 10.1002/mds.30271.
    PubMed    


  94. ZHANG G, Guan L, Gao Y, Shi L, et al
    Sleep Stage Classification Using Subthalamic Nucleus Local Field Potentials Following Long-Term Neuromodulation in Parkinson's Disease.
    Mov Disord. 2025 Jun 12. doi: 10.1002/mds.30264.
    PubMed    


  95. RICCIARDI L, Cucinotta F, Pegolo E, Abundes-Corona A, et al
    Low/High Multi-Frequency Stimulation of the Subthalamic Nucleus Improves Verbal Fluency Maintaining Motor Control in Parkinson's Disease.
    Mov Disord. 2025 Jun 11. doi: 10.1002/mds.30254.
    PubMed     Abstract available


  96. MULLER T, Kuhn W
    Is Hypomethylation of the alpha-Synuclein Gene in Parkinson's Disease Patients Related to Chronic Levodopa Intake?
    Mov Disord. 2025 Jun 9. doi: 10.1002/mds.30263.
    PubMed    


  97. ERRO R, Sorrentino C, Barone P
    Plastamination: A Rising Concern for Parkinson's Disease.
    Mov Disord. 2025 Jun 3. doi: 10.1002/mds.30253.
    PubMed    


  98. LIAO Y, Wu H, Wang J, Corvol JC, et al
    Genetic Analysis of the X Chromosome Associates Loci with Progression of Parkinson's Disease.
    Mov Disord. 2025 Jun 3. doi: 10.1002/mds.30252.
    PubMed     Abstract available


  99. ANANDAPADMANABHAN R, Vishnoi A, Raman G, Thachan J, et al
    Deep Learning-Based Artificial Intelligence Algorithm to Classify Tremors from Hand-Drawn Spirals.
    Mov Disord. 2025;40:1172-1181.
    PubMed     Abstract available


    May 2025
  100. GROS P, Marras C, Wang X, Chiu M, et al
    Differences in Parkinson's Disease Populations: Teaching Hospitals Versus Other Settings and Implications for Clinical Trials.
    Mov Disord. 2025 May 29. doi: 10.1002/mds.30239.
    PubMed     Abstract available


  101. DHAWAN V, Peng S, Spetsieris PG, Eidelberg D, et al
    Positron Emission Tomography Imaging in Clinical Trials for Parkinson's Disease: Applications of Metabolic Brain Network Approach.
    Mov Disord. 2025 May 29. doi: 10.1002/mds.30231.
    PubMed     Abstract available


  102. WEINTRAUB D, Brumm MC, Kurth R, York MK, et al
    Reply to: "Use of Robust Norming to Create a Sensitive Cognitive Summary Score in De Novo Parkinson's Disease: An Illustrative Example".
    Mov Disord. 2025 May 29. doi: 10.1002/mds.30247.
    PubMed    


  103. GONZALEZ DA, Karstens AJ, Patel SES, Fleisher JE, et al
    The Parkinson's Disease Cognitive Composite: Lessons Forgotten from Preclinical Alzheimer's Cognitive Composites.
    Mov Disord. 2025 May 29. doi: 10.1002/mds.30246.
    PubMed    


  104. FERESHTEHNEJAD SM, Moqadam R, Azizi H, Postuma RB, et al
    Distinct Longitudinal Clinical-Neuroanatomical Trajectories in Parkinson's Disease Clinical Subtypes: Insight toward Precision Medicine.
    Mov Disord. 2025 May 26. doi: 10.1002/mds.30229.
    PubMed     Abstract available


  105. WALSHE M, Hirschwald J, Warnecke T
    Measuring What Matters in Parkinson's Disease Research and Dysphagia: The Need for Core Outcome Sets.
    Mov Disord. 2025 May 23. doi: 10.1002/mds.30241.
    PubMed    


  106. VAZIRIAN F, Tian J, Cicuttini F, Jones G, et al
    Reply to: "Chronic Pain and Parkinson's Disease: Causation or Confounding?".
    Mov Disord. 2025 May 23. doi: 10.1002/mds.30234.
    PubMed    


  107. XU QH, Wang YL, Zhang BR, Tian J, et al
    Chronic Pain and Parkinson's Disease: Causation or Confounding?
    Mov Disord. 2025 May 23. doi: 10.1002/mds.30235.
    PubMed    


  108. AAMODT WW, Eickholt L, Coughlin DG, Solomon L, et al
    Sex and Racial/Ethnic Differences in End-of-Life Care Preferences in Persons with Parkinson's Disease and Related Disorders.
    Mov Disord. 2025 May 23. doi: 10.1002/mds.30240.
    PubMed     Abstract available


  109. VAN LAAR AD, Christine CW, Phielipp N, Larson PS, et al
    Intraputaminal Delivery of Adeno-Associated Virus Serotype 2-Glial Cell Line-Derived Neurotrophic Factor in Mild or Moderate Parkinson's Disease.
    Mov Disord. 2025 May 20. doi: 10.1002/mds.30193.
    PubMed     Abstract available


  110. GAN-OR Z, Alcalay RN
    LRRK2-Associated Parkinson's Disease: Is it a Synucleinopathy After All?
    Mov Disord. 2025 May 19. doi: 10.1002/mds.30228.
    PubMed    


  111. AFAAR F, Youssef P, Galper J, Chua M, et al
    Peripheral Mononuclear Cell Mitochondrial Function Associates with T-Cell Cytokines in Parkinson's Disease.
    Mov Disord. 2025 May 16. doi: 10.1002/mds.30233.
    PubMed     Abstract available


  112. PONS R, Pearson TS, Perez-Duenas B, Garcia-Cazorla A, et al
    Development and Preliminary Validation of a Parkinsonism-Dystonia Scale for Infants and Young Children.
    Mov Disord. 2025 May 13. doi: 10.1002/mds.30219.
    PubMed     Abstract available


  113. SUPPA A, Asci F, Kamble N, Chen KH, et al
    Neurophysiology of Atypical Parkinsonian Syndromes: A Study Group Position Paper.
    Mov Disord. 2025 May 12. doi: 10.1002/mds.30225.
    PubMed     Abstract available


  114. STRANIERO L, Rimoldi V, Cereda E, Solda G, et al
    Genetics Influences Telomere Length in Parkinson's Disease: A Study in Monozygotic Discordant Twins.
    Mov Disord. 2025 May 9. doi: 10.1002/mds.30224.
    PubMed     Abstract available


  115. YUCEL M, Odorfer T, Volkmann J, Zeller D, et al
    Revisiting Coactivation ("Froment's Maneuver") in Parkinson's Disease: A Physiological Approach.
    Mov Disord. 2025 May 5. doi: 10.1002/mds.30226.
    PubMed     Abstract available


  116. IMBALZANO G, Montanaro E, Ledda C, Donetto F, et al
    Theta-Gamma Subthalamic Stimulation for Verbal Fluency in Parkinson's Disease: A Randomized, Crossover Trial.
    Mov Disord. 2025 May 5. doi: 10.1002/mds.30218.
    PubMed     Abstract available


    April 2025
  117. PASCHEN S, Natera-Villalba E, Pineda-Pardo JA, Del Alamo M, et al
    Are there Predictors for the Effects of Subthalamic Versus Thalamic Lesions for the Treatment of Parkinsonian Tremor?
    Mov Disord. 2025 Apr 27. doi: 10.1002/mds.30216.
    PubMed    


  118. AUBIGNAT M
    Does Dopamine Sensitivity Influence the Choice between Subthalamotomy and Thalamotomy for Parkinsonian Tremor?
    Mov Disord. 2025 Apr 27. doi: 10.1002/mds.30215.
    PubMed    


  119. DI VICO IA, Moretto M, Tamanti A, Tomelleri G, et al
    Molecular-Informed Network Analysis Unveils Fatigue-Related Functional Connectivity in Parkinson's Disease.
    Mov Disord. 2025 Apr 22. doi: 10.1002/mds.30214.
    PubMed     Abstract available


  120. WEINTRAUB D, Chaudhuri KR, Schrag A, Martinez-Martin P, et al
    Validation of the International Parkinson and Movement Disorder Society Non-Motor Symptoms Questionnaire (MDS-NMS-Q).
    Mov Disord. 2025 Apr 18. doi: 10.1002/mds.30202.
    PubMed     Abstract available


  121. WIESMAN AI, Vinding MC, Tsitsi P, Svenningsson P, et al
    Cortical Effects of Dopamine Replacement Account for Clinical Response Variability in Parkinson's Disease.
    Mov Disord. 2025 Apr 18. doi: 10.1002/mds.30200.
    PubMed     Abstract available


  122. SMITH MD, Portlock GE, Cullen A, Nodehi A, et al
    Transcutaneous Tibial Nerve Stimulation for Overactive Bladder Symptoms in Parkinson's Disease: Results from a Phase II Randomized Control Trial (STRIPE).
    Mov Disord. 2025 Apr 17. doi: 10.1002/mds.30186.
    PubMed     Abstract available


  123. CHOU KL, Kanel P, van Emde Boas M, Roytman S, et al
    Cholinergic System Changes in Dopa-Unresponsive Freezing of Gait in Parkinson's Disease.
    Mov Disord. 2025 Apr 11. doi: 10.1002/mds.30196.
    PubMed     Abstract available


  124. LAMOS M, Bockova M, Missey F, Lubrano C, et al
    Noninvasive Temporal Interference Stimulation of the Subthalamic Nucleus in Parkinson's Disease Reduces Beta Activity.
    Mov Disord. 2025 Apr 9. doi: 10.1002/mds.30134.
    PubMed     Abstract available


  125. SCHOENWALD H, Bahners BH, Kannenberg S, Dembek TA, et al
    Antero-Lateral Subthalamic Nucleus Theta Stimulation Improves Verbal Fluency in Parkinson's Disease.
    Mov Disord. 2025 Apr 2. doi: 10.1002/mds.30185.
    PubMed     Abstract available


  126. CARRA RB, Garcia LAL, Menezes JR, Capato T, et al
    Spinal Cord Stimulation Failed to Improve Parkinson's Disease Symptoms in Randomized Crossover Double-Blinded Evaluation.
    Mov Disord. 2025 Apr 2. doi: 10.1002/mds.30187.
    PubMed     Abstract available


  127. AMMANN C, Pagge C, Wilhelm E, Galletti C, et al
    Motor Cortex Disinhibition Correlates with Olfactory Dysfunction in Parkinson's Disease.
    Mov Disord. 2025 Apr 1. doi: 10.1002/mds.30171.
    PubMed     Abstract available


  128. LIU H, Zhu Q, Wang J, Qin C, et al
    Assessment of Piezo1 Expression in Urinary Exfoliated Cells as a Diagnostic Indicator for Multiple System Atrophy.
    Mov Disord. 2025;40:759-764.
    PubMed     Abstract available


  129. ROSSI M, Schaake S, Usnich T, Boehm J, et al
    Classification and Genotype-Phenotype Relationships of GBA1 Variants: MDSGene Systematic Review.
    Mov Disord. 2025;40:605-618.
    PubMed     Abstract available


  130. TRUJILLO P, O'Rourke KR, Roman OC, Song AK, et al
    Central Involvement in Pure Autonomic Failure: Insights from Neuromelanin-Sensitive Magnetic Resonance Imaging and (18)F-Fluorodopa-Positron Emission Tomography.
    Mov Disord. 2025;40:716-726.
    PubMed     Abstract available


    March 2025
  131. BEZDICEK O, Biundo R, Boelema S, Cammisuli DM, et al
    Neuropsychological Tests of Memory, Visuospatial, and Language Function in Parkinson's Disease: Review, Critique, and Recommendations.
    Mov Disord. 2025 Mar 27. doi: 10.1002/mds.30166.
    PubMed     Abstract available


  132. GARON M, Rojo-Albuin JM, Chaudhuri KR, Rizos A, et al
    Conversion between NMSS and MDS-NMS in Parkinson's Disease.
    Mov Disord. 2025 Mar 20. doi: 10.1002/mds.30172.
    PubMed     Abstract available


  133. TOTSUNE T, Baba T, Hasegawa T, Takeda A, et al
    The Heart of the Matter: Cardiac Denervation Casts Doubt on the Brain-First Versus Body-First Hypothesis of Parkinson's Disease.
    Mov Disord. 2025 Mar 18. doi: 10.1002/mds.30174.
    PubMed    


  134. MESTRE TA, Sampaio C
    Is Parkinson Disease Better Defined Solely by Biology or as a Clinical-Biological Entity? Lessons to be Learned from Alzheimer's Disease on Biological Definition and Staging.
    Mov Disord. 2025 Mar 18. doi: 10.1002/mds.30173.
    PubMed    


  135. YAN R, Zheng X, Yin Y, Zhang J, et al
    Treatment for Dyskinesia in Parkinson's Disease: A Network Meta-analysis of Randomized Controlled Trials.
    Mov Disord. 2025 Mar 18. doi: 10.1002/mds.30179.
    PubMed     Abstract available


  136. BEHNKE JK, Peach RL, Habets JGV, Busch JL, et al
    Long-Term Stability of Spatial Distribution and Peak Dynamics of Subthalamic Beta Power in Parkinson's Disease Patients.
    Mov Disord. 2025 Mar 18. doi: 10.1002/mds.30169.
    PubMed     Abstract available


  137. SVENNINGSSON P, Odin P, Bergquist F, Wirdefeldt K, et al
    NLX-112 Randomized Phase 2A Trial: Safety, Tolerability, Anti-Dyskinetic, and Anti-Parkinsonian Efficacy.
    Mov Disord. 2025 Mar 17. doi: 10.1002/mds.30175.
    PubMed     Abstract available


  138. WILPERT NM, Hewitt AL, Pons R, Henke MT, et al
    Patients with Allan-Herndon-Dudley Syndrome (MCT8 Deficiency) Display Symptoms of Parkinsonism in Childhood and Respond to Levodopa/Carbidopa Treatment.
    Mov Disord. 2025 Mar 15. doi: 10.1002/mds.30152.
    PubMed     Abstract available


  139. COLOMBO A, Bernasconi E, Alva L, Sousa M, et al
    Finely Tuned gamma Tracks Medication Cycles in Parkinson's Disease: An Ambulatory Brain-Sense Study.
    Mov Disord. 2025 Mar 13. doi: 10.1002/mds.30160.
    PubMed     Abstract available


  140. DE BIE RMA, Katzenschlager R, Swinnen BEKS, Peball M, et al
    Update on Treatments for Parkinson's Disease Motor Fluctuations - An International Parkinson and Movement Disorder Society Evidence-Based Medicine Review.
    Mov Disord. 2025 Mar 8. doi: 10.1002/mds.30162.
    PubMed     Abstract available


  141. PASCHEN S, Natera-Villalba E, Pineda-Pardo JA, Del Alamo M, et al
    Comparative Study of Focused Ultrasound Unilateral Thalamotomy and Subthalamotomy for Medication-Refractory Parkinson's Disease Tremor.
    Mov Disord. 2025 Mar 3. doi: 10.1002/mds.30159.
    PubMed     Abstract available


    February 2025
  142. YAO P, Sharma A, Abdi-Sargezeh B, Liu T, et al
    Beta Burst Characteristics and Coupling within the Sensorimotor Cortical-Subthalamic Nucleus Circuit Dynamically Relate to Bradykinesia in Parkinson's Disease.
    Mov Disord. 2025 Feb 27. doi: 10.1002/mds.30163.
    PubMed     Abstract available


  143. SU D, Ji L, Cui Y, Gan L, et al
    Altered Visuomotor Network Dynamics Associated with Freezing of Gait in Parkinson's Disease.
    Mov Disord. 2025 Feb 25. doi: 10.1002/mds.30146.
    PubMed     Abstract available


  144. NI Y, Yin YN, Yu WB, Liu YQ, et al
    Assessing Plasma APLP1 for the Progression of Parkinson's Disease: Insights from HSPD and PPMI Cohorts.
    Mov Disord. 2025 Feb 19. doi: 10.1002/mds.30154.
    PubMed     Abstract available


  145. SONG S, Luo Z, Plassman BL, Huang X, et al
    Self-Reported Motor and Nonmotor Symptoms, Prodromal Parkinson's Disease Probability, and Incident Parkinson's Disease in US Farmers.
    Mov Disord. 2025 Feb 14. doi: 10.1002/mds.30149.
    PubMed     Abstract available


  146. SUN S, Madge V, Djordjevic J, Gagnon JF, et al
    Selective Effects of Substantia Nigra and Locus Coeruleus Degeneration on Cognition in Parkinson's Disease.
    Mov Disord. 2025 Feb 13. doi: 10.1002/mds.30148.
    PubMed     Abstract available


  147. WALLIN J, Forsberg A, Svenningsson P
    Effects of Montelukast on Neuroinflammation in Parkinson's Disease: An Open Label Safety and Tolerability Trial with CSF Markers and [(11)C]PBR28 PET.
    Mov Disord. 2025 Feb 6. doi: 10.1002/mds.30144.
    PubMed     Abstract available


  148. SANTOS-LOBATO BL
    New Insights into the Association of Pesticide Exposure and Parkinson's Disease.
    Mov Disord. 2025 Feb 5. doi: 10.1002/mds.30135.
    PubMed    


  149. JANSSEN DAALEN J, van der Heiden M, Meinders M, Post B, et al
    Motor Symptom Variability in Parkinson's Disease: Implications for Personalized Trial Outcomes?
    Mov Disord. 2025 Feb 5. doi: 10.1002/mds.30133.
    PubMed     Abstract available


  150. WU Y, Xu W
    Addressing Methodological Variability and Enhancing Efficacy Assessment in Focused Ultrasound Thalamotomy for Parkinson's Tremor.
    Mov Disord. 2025 Feb 4. doi: 10.1002/mds.30136.
    PubMed    


  151. LO RY
    To Trust or Not to Trust? ICD-Coded Diagnosis of Parkinson's Disease.
    Mov Disord. 2025;40:181-183.
    PubMed    


  152. WIEST C, Simpson TG, Pogosyan A, Hasegawa H, et al
    Stimulation-Evoked Resonant Neural Activity in the Subthalamic Nucleus Is Modulated by Sleep.
    Mov Disord. 2025;40:351-356.
    PubMed     Abstract available


    January 2025
  153. GIBBON S, Breen DP, MacGillivray TJ
    Optic Disc Pallor in Parkinson's Disease: A UK Biobank Study.
    Mov Disord. 2025 Jan 30. doi: 10.1002/mds.30127.
    PubMed     Abstract available


  154. TOODAYAN N, Lees AJ
    Two London Memorials to "James Parkinson [1755-1824], Esq. Surgeon, Late of Hoxton-Square".
    Mov Disord. 2025 Jan 24. doi: 10.1002/mds.30115.
    PubMed     Abstract available


  155. FU Y, Adler GL, Youssef P, Phan K, et al
    Human Endogenous Retrovirus K in Astrocytes Is Altered in Parkinson's Disease.
    Mov Disord. 2025 Jan 22. doi: 10.1002/mds.30128.
    PubMed     Abstract available


  156. BRACCIA A, Golfre Andreasi N, Ghielmetti F, Aquino D, et al
    Magnetic Resonance-Guided Focused Ultrasound Thalamotomy in a Prospective Cohort of 52 Patients with Parkinson's Disease: A Possible Critical Role of Age and Lesion Volume for Predicting Tremor Relapse.
    Mov Disord. 2025 Jan 18. doi: 10.1002/mds.30093.
    PubMed     Abstract available


  157. LIANG M, Chu L, Yue Z
    New Multiomic Studies Shed Light on Cellular Diversity and Neuronal Susceptibility in Parkinson's Disease.
    Mov Disord. 2025 Jan 15. doi: 10.1002/mds.30097.
    PubMed     Abstract available


  158. FALLETTI M, Asci F, Zampogna A, Patera M, et al
    Rigidity in Parkinson's Disease: The Objective Effect of Levodopa.
    Mov Disord. 2025 Jan 8. doi: 10.1002/mds.30114.
    PubMed     Abstract available


  159. WEINTRAUB D, Brumm MC, Kurth R, York MK, et al
    Use of Robust Norming to Create a Sensitive Cognitive Summary Score in De Novo Parkinson's Disease: An Illustrative Example.
    Mov Disord. 2025 Jan 6. doi: 10.1002/mds.30111.
    PubMed     Abstract available


  160. JO S, Oh JH, Lee EJ, Choi M, et al
    Mitochondrial DNA Copy Number as a Potential Biomarker for the Severity of Motor Symptoms and Prognosis in Parkinson's Disease.
    Mov Disord. 2025 Jan 6. doi: 10.1002/mds.30098.
    PubMed     Abstract available


  161. GUSTAVSSON EK
    Editorial on: Confirmation of RAB32 Ser71Arg involvement in Parkinson's disease.
    Mov Disord. 2025;40:5-6.
    PubMed    


    December 2024
  162. TSAI SY, Tai CH, Lee YY
    Use of Transcranial Magnetic Stimulation to Probe Neuroplasticity and Predict Gait Performance After Treadmill Training in Parkinson's Disease.
    Mov Disord. 2024 Dec 31. doi: 10.1002/mds.30100.
    PubMed     Abstract available


  163. MAGISTRELLI L, Brumana M, Rimoldi V, Poggi-Longostrevi S, et al
    The RAB32 p.Ser71Arg Variant in Parkinsonisms: Insights from a Large Italian Cohort.
    Mov Disord. 2024 Dec 31. doi: 10.1002/mds.30103.
    PubMed     Abstract available


  164. RODRIGUEZ-OROZ MC, Martinez-Fernandez R, Lipsman N, Horisawa S, et al
    Bilateral Lesions in Parkinson's Disease: Gaps and Controversies.
    Mov Disord. 2024 Dec 27. doi: 10.1002/mds.30090.
    PubMed     Abstract available


  165. DE MENA L, Pares G, Garrido A, Pilco-Janeta DF, et al
    alpha-Synuclein Gene Hypomethylation in LRRK2 Parkinson's Disease Patients.
    Mov Disord. 2024 Dec 23. doi: 10.1002/mds.30094.
    PubMed     Abstract available


  166. GUAN L, Yu H, Chen Y, Gong C, et al
    Subthalamic gamma Oscillation Underlying Rapid Eye Movement Sleep Abnormality in Parkinsonian Patients.
    Mov Disord. 2024 Dec 20. doi: 10.1002/mds.30091.
    PubMed     Abstract available


  167. GRILLO P, Concha-Marambio L, Pisani A, Riboldi GM, et al
    Association between the Amplification Parameters of the alpha-Synuclein Seed Amplification Assay and Clinical and Genetic Subtypes of Parkinson's Disease.
    Mov Disord. 2024 Dec 18. doi: 10.1002/mds.30085.
    PubMed     Abstract available


  168. VAN DEN BERG KRE, Johansson ME, Dirkx MF, Bloem BR, et al
    Changes in Action Tremor in Parkinson's Disease over Time: Clinical and Neuroimaging Correlates.
    Mov Disord. 2024 Dec 16. doi: 10.1002/mds.30081.
    PubMed     Abstract available


  169. LEE CH, Juan CH, Chen HH, Hong JP, et al
    Long-Range Temporal Correlations in Electroencephalography for Parkinson's Disease Progression.
    Mov Disord. 2024 Dec 11. doi: 10.1002/mds.30074.
    PubMed     Abstract available


  170. CERNERA S, Oehrn CR, Hammer LH, Shcherbakova M, et al
    Sustained Clinical Benefit of Adaptive Deep Brain Stimulation in Parkinson's Disease Using Gamma Oscillations: A Case Report.
    Mov Disord. 2024 Dec 4. doi: 10.1002/mds.30076.
    PubMed     Abstract available


  171. GOLDMAN SM, Weaver FM, Cao L, Gonzalez B, et al
    Validation of Parkinson's Disease Ascertainment in the Veterans Administration Electronic Medical Record.
    Mov Disord. 2024 Dec 4. doi: 10.1002/mds.30075.
    PubMed     Abstract available


  172. WOO KA, Yoon EJ, Kim S, Kim H, et al
    Cognitive Impact of beta-Amyloid Load in the Rapid Eye Movement Sleep Behavior Disorder-Lewy Body Disease Continuum.
    Mov Disord. 2024;39:2259-2270.
    PubMed     Abstract available


    November 2024
  173. RABANO-SUAREZ P, Del Campo N, Benatru I, Moreau C, et al
    Digital Outcomes as Biomarkers of Disease Progression in Early Parkinson's Disease: A Systematic Review.
    Mov Disord. 2024 Nov 29. doi: 10.1002/mds.30056.
    PubMed     Abstract available


  174. CONTI M, D'Onofrio V, Bovenzi R, Ferrari V, et al
    Cortical Functional Connectivity Changes in the Body-First and Brain-First Subtypes of Parkinson's Disease.
    Mov Disord. 2024 Nov 29. doi: 10.1002/mds.30071.
    PubMed     Abstract available


  175. ATTERLING BROLIN K, Schaeffer E, Kuri A, Rumrich IK, et al
    Environmental Risk Factors for Parkinson's Disease: A Critical Review and Policy Implications.
    Mov Disord. 2024 Nov 27. doi: 10.1002/mds.30067.
    PubMed     Abstract available


  176. HERZ DM, Blech J, Winter Y, Gonzalez-Escamilla G, et al
    Low-Frequency Deep Brain Stimulation in Non-Rapid Eye Movement Sleep Modifies Memory Retention in Parkinson's Disease.
    Mov Disord. 2024 Nov 21. doi: 10.1002/mds.30064.
    PubMed     Abstract available


  177. WANG S, Ou R, Huang J, Lin J, et al
    RAB32 Variants in a Chinese Parkinson's Disease Cohort.
    Mov Disord. 2024 Nov 21. doi: 10.1002/mds.30065.
    PubMed    


  178. KOSZYCKI D, Taljaard M, Bradwejn J, Lee C, et al
    Interpersonal Psychotherapy for the Treatment of Depression in Parkinson's Disease: Results of a Randomized Controlled Trial.
    Mov Disord. 2024 Nov 20. doi: 10.1002/mds.30061.
    PubMed     Abstract available


  179. ZHAO Y, Lai Y, Darweesh SKL, Bloem BR, et al
    Gut Microbial Metabolites and Future Risk of Parkinson's Disease: A Metabolome-Wide Association Study.
    Mov Disord. 2024 Nov 12. doi: 10.1002/mds.30054.
    PubMed     Abstract available


  180. HWANG YS, Jo S, Lee SH, Park KW, et al
    Identification of Novel Genetic Loci Affecting Age at Onset of Parkinson's Disease: A Genome-wide Association Study.
    Mov Disord. 2024 Nov 6. doi: 10.1002/mds.30047.
    PubMed     Abstract available


  181. ZAGARE A, Hemedan A, Almeida C, Frangenberg D, et al
    Insulin Resistance Is a Modifying Factor for Parkinson's Disease.
    Mov Disord. 2024 Nov 5. doi: 10.1002/mds.30039.
    PubMed     Abstract available


  182. VAZIRIAN F, Tian J, Jane Alty, Aitken D, et al
    Chronic Musculoskeletal Pain and Risk of Incident Parkinson's Disease: A 13-Year Longitudinal Study.
    Mov Disord. 2024 Nov 2. doi: 10.1002/mds.30046.
    PubMed     Abstract available


  183. BALACHANDAR A, Hashim Y, Vaou O, Fasano A, et al
    Automated Sleep Detection in Movement Disorders Using Deep Brain Stimulation and Machine Learning.
    Mov Disord. 2024;39:2097-2102.
    PubMed     Abstract available


  184. LOPICCOLO MK, Wang Z, Eshed GM, Fierro L, et al
    Skin alpha-Synuclein Seeding Activity in Patients with Type 1 Gaucher Disease.
    Mov Disord. 2024;39:2087-2091.
    PubMed     Abstract available


    October 2024
  185. CAO S, Fang X, Wang J, Sun Y, et al
    Skin Biopsy Detection of Phosphorylated alpha-Synuclein in Patients of Bullous Pemphigoid with or without Parkinson's Disease.
    Mov Disord. 2024 Oct 31. doi: 10.1002/mds.30045.
    PubMed     Abstract available


  186. STEP K, Eltaraifee E, Elsayed I, Rasaholiarison N, et al
    Advancing Parkinson's Disease Research in Africa: A Strategic Training Framework of the Global Parkinson's Genetics Program.
    Mov Disord. 2024 Oct 31. doi: 10.1002/mds.30051.
    PubMed    


  187. RADEFELDT M, Lemke S, Chaichoompu K, Paul JJ, et al
    Genetic and Epidemiological Insights into RAB32-Linked Parkinson's Disease.
    Mov Disord. 2024 Oct 26. doi: 10.1002/mds.30041.
    PubMed     Abstract available


  188. MAHAJAN A, Morrow CB, Seemiller J, Mills KA, et al
    The Effect of Dysautonomia on Motor, Behavioral, and Cognitive Fluctuations in Parkinson's Disease.
    Mov Disord. 2024 Oct 25. doi: 10.1002/mds.30044.
    PubMed     Abstract available


  189. EMMI A, Macchi V, Stocco E, Tushevski A, et al
    alpha-Synuclein Pathology in the Carotid Body: Experimental Evidence for a possible Contributor to Respiratory Impairment in Parkinson's Disease.
    Mov Disord. 2024 Oct 24. doi: 10.1002/mds.30036.
    PubMed    


  190. AJALIN R, Al-Abdulrasul H, Tuisku JM, Hirvonen J, et al
    Impaired Gait, Postural Instability, and Rigidity in Relation to CB1 Receptor Availability in Parkinson's Disease.
    Mov Disord. 2024 Oct 22. doi: 10.1002/mds.30042.
    PubMed     Abstract available


  191. HINES K, Noecker AM, Frankemolle-Gilbert AM, Liang TW, et al
    Prospective Connectomic-Based Deep Brain Stimulation Programming for Parkinson's Disease.
    Mov Disord. 2024 Oct 21. doi: 10.1002/mds.30026.
    PubMed     Abstract available


  192. SLATER NM, Melzer TR, Myall DJ, Anderson TJ, et al
    Cholinergic Basal Forebrain Integrity and Cognition in Parkinson's Disease: A Reappraisal of Magnetic Resonance Imaging Evidence.
    Mov Disord. 2024 Oct 3. doi: 10.1002/mds.30023.
    PubMed     Abstract available


  193. CHURCHILL L, Chen YC, Lewis SJG, Matar E, et al
    Understanding REM Sleep Behavior Disorder through Functional MRI: A Systematic Review.
    Mov Disord. 2024;39:1679-1696.
    PubMed     Abstract available


  194. KHOSOUSI S, Sturchio A, Appleton E, Paslawski W, et al
    Increased CSF DOPA Decarboxylase Correlates with Lower DaT-SPECT Binding: Analyses in Biopark and PPMI Cohorts.
    Mov Disord. 2024;39:1881-1885.
    PubMed     Abstract available


    September 2024
  195. COGAN G, Tesson C, Brefel-Courbon C, Lanore A, et al
    Confirmation of RAB32 Ser71Arg Involvement in Parkinson's Disease.
    Mov Disord. 2024 Sep 23. doi: 10.1002/mds.30024.
    PubMed    


  196. GABBERT C, Shambetova C, Much C, Trinh J, et al
    RAB32 Variants in a German Parkinson's Disease Cohort.
    Mov Disord. 2024 Sep 19. doi: 10.1002/mds.30005.
    PubMed    


  197. ARMENGOU-GARCIA L, Sanchez-Catasus CA, Aviles-Olmos I, Jimenez-Huete A, et al
    Unilateral Magnetic Resonance-Guided Focused Ultrasound Lesion of the Subthalamic Nucleus in Parkinson's Disease: A Prospective Study.
    Mov Disord. 2024 Sep 18. doi: 10.1002/mds.30020.
    PubMed     Abstract available


  198. TANIGUCHI S, Kajiyama Y, Kochiyama T, Revankar G, et al
    New Insights into Freezing of Gait in Parkinson's Disease from Spectral Dynamic Causal Modeling.
    Mov Disord. 2024 Sep 18. doi: 10.1002/mds.29988.
    PubMed     Abstract available


  199. VIEIRA SRL, Mezabrovschi R, Toffoli M, Del Pozo SL, et al
    Consensus Guidance for Genetic Counseling in GBA1 Variants: A Focus on Parkinson's Disease.
    Mov Disord. 2024 Sep 11. doi: 10.1002/mds.30006.
    PubMed     Abstract available


  200. KALIA LV, Berg D, Kordower JH, Shannon KM, et al
    Movement Disorders Society Viewpoint on Biological Frameworks of Parkinson's Disease: Current Status and Future Directions.
    Mov Disord. 2024 Sep 9. doi: 10.1002/mds.30007.
    PubMed    


  201. DZIALAS V, Doering E, Eich H, Strafella AP, et al
    Houston, We Have AI Problem! Quality Issues with Neuroimaging-Based Artificial Intelligence in Parkinson's Disease: A Systematic Review.
    Mov Disord. 2024 Sep 5. doi: 10.1002/mds.30002.
    PubMed     Abstract available


  202. NIEMI KJ, Sunikka J, Soltanian-Zadeh H, Davoodi-Bojd E, et al
    Rest Tremor in Parkinson's Disease Is Associated with Ipsilateral Striatal Dopamine Transporter Binding.
    Mov Disord. 2024 Sep 3. doi: 10.1002/mds.29997.
    PubMed     Abstract available


  203. WIJERS A, Ravi A, Evers SMAA, Tissingh G, et al
    Systematic Review of the Cost of Illness of Parkinson's Disease from a Societal Perspective.
    Mov Disord. 2024 Sep 2. doi: 10.1002/mds.29995.
    PubMed     Abstract available



  204. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S809-S858.
    PubMed    



  205. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S199-S213.
    PubMed    



  206. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S593-S739.
    PubMed    



  207. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S290-S353.
    PubMed    



  208. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S435-S592.
    PubMed    



  209. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S241-S289.
    PubMed    



  210. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S740-S808.
    PubMed    



  211. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S214-S240.
    PubMed    



  212. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S859-S896.
    PubMed    



  213. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S1-S99.
    PubMed    



  214. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S100-S198.
    PubMed    



  215. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S354-S434.
    PubMed    


    August 2024
  216. METCALFE-ROACH A, Cirstea MS, Yu AC, Ramay HR, et al
    Metagenomic Analysis Reveals Large-Scale Disruptions of the Gut Microbiome in Parkinson's Disease.
    Mov Disord. 2024 Aug 28. doi: 10.1002/mds.29959.
    PubMed     Abstract available


  217. TANG H, Lu Y, Okun MS, Donahoo WT, et al
    Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A Population-Based Cohort Study.
    Mov Disord. 2024 Aug 27. doi: 10.1002/mds.29992.
    PubMed     Abstract available


  218. GUIDA P, Martinez-Fernandez R, Manez-Miro JU, Del Alamo M, et al
    Social Cognition in Parkinson's Disease after Focused Ultrasound Subthalamotomy: A Controlled Study.
    Mov Disord. 2024 Aug 14. doi: 10.1002/mds.29945.
    PubMed     Abstract available


  219. LAZARO-FIGUEROA A, Hernandez-Medrano AJ, Ramirez-Pineda DB, Navarro Cadavid A, et al
    Is SH3GL2 p.G276V the Causal Functional Variant Underlying Parkinson's Disease Risk at this Locus?
    Mov Disord. 2024 Aug 12. doi: 10.1002/mds.29719.
    PubMed    


  220. YANG C, Xu Y, Feng X, Wang B, et al
    Transcranial Temporal Interference Stimulation of the Right Globus Pallidus in Parkinson's Disease.
    Mov Disord. 2024 Aug 12. doi: 10.1002/mds.29967.
    PubMed     Abstract available


  221. SOSERO YL, Bandres-Ciga S, Ferwerda B, Tocino MTP, et al
    Dopamine Pathway and Parkinson's Risk Variants Are Associated with Levodopa-Induced Dyskinesia.
    Mov Disord. 2024 Aug 12. doi: 10.1002/mds.29960.
    PubMed     Abstract available


  222. CHEYUO C, Germann J, Yamamoto K, Zibly Z, et al
    Probabilistic Refinement of Focused Ultrasound Thalamotomy Targeting for Parkinson's Disease Tremor.
    Mov Disord. 2024 Aug 9. doi: 10.1002/mds.29965.
    PubMed     Abstract available


  223. MATAR E, Tinazzi M, Edwards MJ, Bhatia KP, et al
    Functional Movement Disorder as a Prodromal Symptom of Parkinson's Disease-Clinical and Pathophysiological Insights.
    Mov Disord. 2024 Aug 9. doi: 10.1002/mds.29958.
    PubMed     Abstract available


  224. KIKUYA A, Tsukita K, Sawamura M, Yoshimura K, et al
    Distinct Clinical Implications of Patient- Versus Clinician-Rated Motor Symptoms in Parkinson's Disease.
    Mov Disord. 2024 Aug 2. doi: 10.1002/mds.29962.
    PubMed     Abstract available


  225. TIAN Q, Ding J
    Advancing Parkinson's Research through Psychological Assessments of Deep Brain Stimulation Effects.
    Mov Disord. 2024;39:1429-1430.
    PubMed    


  226. XIAO H, Lang L, Ye Z, Wu J, et al
    Advancing Parkinson's Research: Considerations and Future Directions.
    Mov Disord. 2024;39:1430-1431.
    PubMed    


  227. SONG P, Krainc D
    Diverse Functions of Parkin in Midbrain Dopaminergic Neurons.
    Mov Disord. 2024;39:1282-1288.
    PubMed     Abstract available


  228. ZHENG Y, Yu Z, Cai H, Kou W, et al
    Detection of alpha-Synuclein in Oral Mucosa by Seed Amplification Assay in Synucleinopathies and Isolated REM Sleep Behavior Disorder.
    Mov Disord. 2024;39:1300-1309.
    PubMed     Abstract available


  229. AMRAMI A, Singh NA, Ali F, Pham NTT, et al
    Clinical Utility of Tectal Plate Measurements on Magnetic Resonance Imaging in Progressive Supranuclear Palsy.
    Mov Disord. 2024;39:1402-1407.
    PubMed     Abstract available


    July 2024
  230. VIRAMETEEKUL S, Lees AJ, Bhidayasiri R
    Small Particles, Big Potential: Polymeric Nanoparticles for Drug Delivery in Parkinson's Disease.
    Mov Disord. 2024 Jul 30. doi: 10.1002/mds.29939.
    PubMed     Abstract available


  231. JUNKER J, Lange LM, Vollstedt EJ, Roopnarain K, et al
    Team Science Approaches to Unravel Monogenic Parkinson's Disease on a Global Scale.
    Mov Disord. 2024 Jul 30. doi: 10.1002/mds.29925.
    PubMed     Abstract available


  232. BELLINI G, Rettura F, Palermo G, Ippolito C, et al
    Prokineticin-2 Is Highly Expressed in Colonic Mucosa of Early Parkinson's Disease Patients.
    Mov Disord. 2024 Jul 25. doi: 10.1002/mds.29937.
    PubMed     Abstract available


  233. GOEDE LL, Oxenford S, Kroneberg D, Meyer GM, et al
    Linking Invasive and Noninvasive Brain Stimulation in Parkinson's Disease: A Randomized Trial.
    Mov Disord. 2024 Jul 25. doi: 10.1002/mds.29940.
    PubMed     Abstract available


  234. LORENZO-BETANCOR O, Mehta S, Ramchandra J, Mumuney S, et al
    Parkinson's Disease Gene Screening in Familial Cases from Central and South America.
    Mov Disord. 2024 Jul 25. doi: 10.1002/mds.29931.
    PubMed     Abstract available


  235. GIBSON LL, Weintraub D, Lemmen R, Perera G, et al
    Risk of Dementia in Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Mov Disord. 2024 Jul 22. doi: 10.1002/mds.29918.
    PubMed     Abstract available


  236. KARIV S, Choi JW, Mirpour K, Gordon AM, et al
    Pilot Study of Acute Behavioral Effects of Pallidal Burst Stimulation in Parkinson's Disease.
    Mov Disord. 2024 Jul 15. doi: 10.1002/mds.29928.
    PubMed     Abstract available


  237. ILLNER V, Novotny M, Kouba T, Tykalova T, et al
    Smartphone Voice Calls Provide Early Biomarkers of Parkinsonism in Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2024 Jul 12. doi: 10.1002/mds.29921.
    PubMed     Abstract available


  238. BERNHARDT AM, Nemati M, Boros FA, Hopfner F, et al
    alpha-Synuclein Seed Amplification Assays from Blood-Based Extracellular Vesicles in Parkinson's Disease: An Evaluation of the Evidence.
    Mov Disord. 2024 Jul 11. doi: 10.1002/mds.29923.
    PubMed    


  239. WOOD KH, Nenert R, Miften AM, Kent GW, et al
    Diffusion Tensor Imaging-Along the Perivascular-Space Index Is Associated with Disease Progression in Parkinson's Disease.
    Mov Disord. 2024 Jul 11. doi: 10.1002/mds.29908.
    PubMed     Abstract available


  240. GOLDMAN SM, Weaver FM, Gonzalez B, Stroupe KT, et al
    Parkinson's Disease Progression and Exposure to Contaminated Water at Camp Lejeune.
    Mov Disord. 2024 Jul 11. doi: 10.1002/mds.29922.
    PubMed     Abstract available


  241. MUSTILE M, Kourtis D, Ladouce S, Edwards MG, et al
    Investigating the Brain Mechanisms of Externally Cued Sit-to-Stand Movement in Parkinson's Disease.
    Mov Disord. 2024 Jul 10. doi: 10.1002/mds.29889.
    PubMed     Abstract available


  242. DE JESUS S, Daya A, Blumberger L, Lewis MM, et al
    Prevalence of Late-Stage Parkinson's Disease in the US Healthcare System: Insights from TriNetX.
    Mov Disord. 2024 Jul 4. doi: 10.1002/mds.29900.
    PubMed     Abstract available


  243. BALTA BEYLERGIL S, Skelly P, Quagraine I, Kilbane C, et al
    Navigating Visual Challenges: How Parkinson's Disease Alters Cognitive Priorities in Visual Search.
    Mov Disord. 2024 Jul 4. doi: 10.1002/mds.29907.
    PubMed     Abstract available


  244. GUO S, Yang G
    Integrating Social Work in Late-Stage Parkinson's Care: A Multifaceted Approach.
    Mov Disord. 2024;39:1249-1250.
    PubMed    


  245. KRUSE C, Dodel R, Schrag A
    Reply to Letter to the Editor-MDS-23-0498.R2/MDS-24-0318.R1.
    Mov Disord. 2024;39:1251-1252.
    PubMed    


  246. ADLER CH, Halverson M, Zhang N, Shill HA, et al
    Conjugal Synucleinopathies: A Clinicopathologic Study.
    Mov Disord. 2024;39:1212-1217.
    PubMed     Abstract available


  247. ZHENG Y, Li Y, Cai H, Kou W, et al
    Alterations of Peripheral Lymphocyte Subsets in Isolated Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2024;39:1179-1189.
    PubMed     Abstract available


    June 2024
  248. BURRE J, Edwards RH, Halliday G, Lang AE, et al
    Research Priorities on the Role of alpha-Synuclein in Parkinson's Disease Pathogenesis.
    Mov Disord. 2024 Jun 30. doi: 10.1002/mds.29897.
    PubMed     Abstract available


  249. AKCIMEN F, van Midden V, Akerman SC, Makarious MB, et al
    Investigating the Protective Role of the Mitochondrial 2158 T > C Variant in Parkinson's Disease.
    Mov Disord. 2024 Jun 28. doi: 10.1002/mds.29892.
    PubMed    


  250. COGAN G, Daida K, Billingsley KJ, Tesson C, et al
    Long-Read Sequencing Unravels the Complexity of Structural Variants in PRKN in Two Individuals with Early-Onset Parkinson's Disease.
    Mov Disord. 2024 Jun 28. doi: 10.1002/mds.29914.
    PubMed    


  251. FABBRI M, Rascol O, Foltynie T, Carroll C, et al
    Advantages and Challenges of Platform Trials for Disease Modifying Therapies in Parkinson's Disease.
    Mov Disord. 2024 Jun 26. doi: 10.1002/mds.29899.
    PubMed     Abstract available


  252. LEODORI G, De Bartolo MI, Piervincenzi C, Mancuso M, et al
    Mapping Motor Cortical Network Excitability and Connectivity Changes in De Novo Parkinson's Disease.
    Mov Disord. 2024 Jun 24. doi: 10.1002/mds.29901.
    PubMed     Abstract available


  253. WANG X, Fu S, Yoo K, Wang X, et al
    Individualized Structural Perturbations on Normative Brain Connectome Restrict Deep Brain Stimulation Outcomes in Parkinson's Disease.
    Mov Disord. 2024 Jun 18. doi: 10.1002/mds.29874.
    PubMed     Abstract available


  254. KIMURA Y, Mochizuki H
    Targeting Glucagon-Like Peptide 1 Signaling: A Potential Disease Modifying Therapy for Parkinson's Disease.
    Mov Disord. 2024 Jun 14. doi: 10.1002/mds.29884.
    PubMed    


  255. BREFEL-COURBON C, Harroch E, Marques A, Devos D, et al
    Oxycodone or Higher Dose of Levodopa for the Treatment of Parkinsonian Central Pain: OXYDOPA Trial.
    Mov Disord. 2024 Jun 8. doi: 10.1002/mds.29878.
    PubMed     Abstract available


  256. JENSEN I, Heine J, Ruf VC, Compta Y, et al
    Impact of Magnetic Resonance Imaging Markers on the Diagnostic Performance of the International Parkinson and Movement Disorder Society Multiple System Atrophy Criteria.
    Mov Disord. 2024 Jun 7. doi: 10.1002/mds.29879.
    PubMed     Abstract available


  257. KORCZYN AD
    Rethinking Parkinson's Disease: A Syndromic Perspective.
    Mov Disord. 2024;39:1079-1080.
    PubMed    


  258. LEODORI G, Mancuso M, Marchet F, Belvisi D, et al
    The Role of the Motor Cortex in the Parkinsonian Tremor Network: Is it Time for an Upgrade?
    Mov Disord. 2024;39:1084.
    PubMed    


  259. OUTEIRO TF, Antonini A, Ferreira JJ
    Reply to: "Rethinking Parkinson's Disease: A Syndromic Perspective".
    Mov Disord. 2024;39:1080-1081.
    PubMed    


  260. SCHNEIDER RB, Mills KA, Nirenberg MJ, Dobkin RD, et al
    Defining the Importance of Minor Hallucinations in Parkinson's Disease.
    Mov Disord. 2024;39:1083.
    PubMed    


  261. OLANOW CW, McIntyre D, Matarazzo M, Leinonen M, et al
    Continuous Levodopa Delivery with an Intraoral Micropump System: An Open-Label Pharmacokinetics and Clinical Study.
    Mov Disord. 2024;39:945-954.
    PubMed     Abstract available


  262. BUUR L, Wiedemann J, Larsen F, Ben Alaya-Fourati F, et al
    Randomized Phase I Trial of the alpha-Synuclein Antibody Lu AF82422.
    Mov Disord. 2024;39:936-944.
    PubMed     Abstract available


  263. SIMONET C, Perez-Carbonell L, Galmes-Ordinas MA, Huxford BFR, et al
    The Motor Dysfunction Seen in Isolated REM Sleep Behavior Disorder.
    Mov Disord. 2024;39:1054-1059.
    PubMed     Abstract available


  264. AVENALI M, Cerri S, Palmieri I, Ongari G, et al
    Functional Study of SNCA p.V15A Variant: Further Linking alpha-Synuclein and Glucocerebrosidase.
    Mov Disord. 2024;39:1060-1065.
    PubMed     Abstract available


    May 2024
  265. GRIPPE T, Shamli-Oghli Y, Darmani G, Nankoo JF, et al
    Plasticity-Induced Effects of Theta Burst Transcranial Ultrasound Stimulation in Parkinson's Disease.
    Mov Disord. 2024 May 24. doi: 10.1002/mds.29836.
    PubMed     Abstract available


  266. VAN MIDDEN V, Simoncic U, Pirtosek Z, Kojovic M, et al
    The Effect of taVNS at 25 Hz and 100 Hz on Parkinson's Disease Gait-A Randomized Motion Sensor Study.
    Mov Disord. 2024 May 17. doi: 10.1002/mds.29826.
    PubMed     Abstract available


  267. ZHANG J, Liu Y, Zhao C
    SNCA-Related Parkinson's Disease Caused by Complete Chromosome 4 Paternal Uniparental Disomy.
    Mov Disord. 2024 May 13. doi: 10.1002/mds.29823.
    PubMed    


  268. HEISS JD, Ray-Chaudhury A, Kleiner DE, Ehrlich DJ, et al
    Persistent GDNF Expression 45 Months after Putaminal Infusion of AAV2-GDNF in a Patient with Parkinson's Disease.
    Mov Disord. 2024 May 8. doi: 10.1002/mds.29820.
    PubMed     Abstract available


  269. XIAO H, Lang L, Ye Z, Wu J, et al
    Subthalamic Nucleus Stimulation Modulates Cognitive Theory of Mind in Parkinson's Disease.
    Mov Disord. 2024 May 2. doi: 10.1002/mds.29830.
    PubMed     Abstract available


  270. MA JH, Dong C, Qiao HW, Barret O, et al
    Striatal and Extrastriatal Monoaminergic Disruption in Progressive Supranuclear Palsy.
    Mov Disord. 2024;39:847-854.
    PubMed     Abstract available


    April 2024
  271. DODET P, Houot M, Leu-Semenescu S, Gaurav R, et al
    Isolated REM Sleep without Atonia Is Not Equivalent to REM Sleep Behavior Disorder in Early-Stage Parkinson's Disease.
    Mov Disord. 2024 Apr 26. doi: 10.1002/mds.29813.
    PubMed     Abstract available


  272. MONCHI O, Pinilla-Monsalve GD, Almgren H, Ghahremani M, et al
    White Matter Microstructural Underpinnings of Mild Behavioral Impairment in Parkinson's Disease.
    Mov Disord. 2024 Apr 25. doi: 10.1002/mds.29804.
    PubMed     Abstract available


  273. SENKEVICH K, Miliukhina I, Zhuravlev A, Shumilova M, et al
    Autosomal Dominant Parkinson's Disease Caused by SNCA p.E46K Mutation in a Family with Russian Ancestry.
    Mov Disord. 2024 Apr 25. doi: 10.1002/mds.29821.
    PubMed    


  274. KLUGE A, Schaeffer E, Bunk J, Sommerauer M, et al
    Detecting Misfolded alpha-Synuclein in Blood Years before the Diagnosis of Parkinson's Disease.
    Mov Disord. 2024 Apr 23. doi: 10.1002/mds.29766.
    PubMed     Abstract available


  275. FREQUIN HL, Verschuur CVM, Suwijn SR, Boel JA, et al
    Long-Term Follow-Up of the LEAP Study: Early Versus Delayed Levodopa in Early Parkinson's Disease.
    Mov Disord. 2024 Apr 21. doi: 10.1002/mds.29796.
    PubMed     Abstract available


  276. WANG Y, Li H, Song N, Xie J, et al
    Yeast Prion Protein Sup35 Initiates alpha-Synuclein Pathology in Parkinson's Disease.
    Mov Disord. 2024 Apr 16. doi: 10.1002/mds.29810.
    PubMed     Abstract available


  277. LASS J, Luth T, Schluter K, Schaake S, et al
    Stability of Mosaic Divergent Repeat Interruptions in X-Linked Dystonia-Parkinsonism.
    Mov Disord. 2024 Apr 14. doi: 10.1002/mds.29809.
    PubMed     Abstract available


  278. SHARMA K, Kishore A, Lechado-Terradas A, Passannanti R, et al
    A Novel PINK1 p.F385S Loss-of-Function Mutation in an Indian Family with Parkinson's Disease.
    Mov Disord. 2024 Apr 8. doi: 10.1002/mds.29792.
    PubMed     Abstract available


  279. NIEMI KJ, Huovinen A, Jaakkola E, Glerean E, et al
    Bodily Maps of Symptoms and Emotions in Parkinson's Disease.
    Mov Disord. 2024 Apr 8. doi: 10.1002/mds.29785.
    PubMed     Abstract available


  280. DU J, Zhang P, Tan Y, Gao C, et al
    Idiopathic Rapid Eye Movement Sleep Behavior Disorder (iRBD) Shares Similar Fecal Short-Chain Fatty Acid Alterations with Multiple System Atrophy (MSA) and Parkinson's Disease (PD).
    Mov Disord. 2024 Apr 1. doi: 10.1002/mds.29803.
    PubMed     Abstract available


  281. ONDER H
    Recurrence of Parkinson's Disease Tremor after Focused Ultrasound Thalamotomy?
    Mov Disord. 2024;39:758-759.
    PubMed    


  282. PETERS J, Maamary J, Kyle K, Olsen N, et al
    Reply to: Recurrence of Parkinson's Disease Tremor after Focused Ultrasound Thalamotomy?
    Mov Disord. 2024;39:759-760.
    PubMed    


  283. BOOGERS A, Fasano A
    Reply to: Comment on: A Transatlantic Viewpoint on the Role of Pallidal Stimulation for Parkinson's Disease.
    Mov Disord. 2024;39:761.
    PubMed    


  284. XIE T, Warnke PC
    Comment on: "A Transatlantic Viewpoint on the Role of Pallidal Stimulation for Parkinson's Disease".
    Mov Disord. 2024;39:760-761.
    PubMed    


  285. PATEL J, Dawson VL, Dawson TM
    Blocking the Self-Destruct Program of Dopamine Neurons through Macrophage Migration Inhibitory Factor Nuclease Inhibition.
    Mov Disord. 2024;39:644-650.
    PubMed     Abstract available


  286. KORNILOV E, Baker Erdman H, Kahana E, Fireman S, et al
    Interleaved Propofol-Ketamine Maintains DBS Physiology and Hemodynamic Stability: A Double-Blind Randomized Controlled Trial.
    Mov Disord. 2024;39:694-705.
    PubMed     Abstract available


  287. STEINA A, Sure S, Butz M, Vesper J, et al
    Mapping Subcortico-Cortical Coupling-A Comparison of Thalamic and Subthalamic Oscillations.
    Mov Disord. 2024;39:684-693.
    PubMed     Abstract available


    March 2024

  288. Correction to "Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus".
    Mov Disord. 2024 Mar 29. doi: 10.1002/mds.29805.
    PubMed    


  289. VERONESE N, Nova A, Fazia T, Riggi E, et al
    Contribution of Nutritional, Lifestyle, and Metabolic Risk Factors to Parkinson's Disease.
    Mov Disord. 2024 Mar 26. doi: 10.1002/mds.29778.
    PubMed     Abstract available


  290. DING H, Nasseroleslami B, Mirzac D, Isaias IU, et al
    Re-emergent Tremor in Parkinson's Disease: Evidence of Pathologic beta and Prokinetic gamma Activity.
    Mov Disord. 2024 Mar 26. doi: 10.1002/mds.29771.
    PubMed     Abstract available


  291. LIU Y, Bainbridge J, Sillau S, Rajkovic S, et al
    Short-Term Cannabidiol with Delta-9-Tetrahydrocannabinol in Parkinson's Disease: A Randomized Trial.
    Mov Disord. 2024 Mar 15. doi: 10.1002/mds.29768.
    PubMed     Abstract available


  292. FRIEDMAN JH
    A New Definition of Psychosis Is Needed in Parkinson's Disease.
    Mov Disord. 2024 Mar 14. doi: 10.1002/mds.29786.
    PubMed    


  293. ZOETEWEI D, Herman T, Ginis P, Palmerini L, et al
    On-Demand Cueing for Freezing of Gait in Parkinson's Disease: A Randomized Controlled Trial.
    Mov Disord. 2024 Mar 14. doi: 10.1002/mds.29762.
    PubMed     Abstract available


  294. CHOUGAR L, Faucher A, Faouzi J, Lejeune FX, et al
    Contribution of MRI for the Early Diagnosis of Parkinsonism in Patients with Diagnostic Uncertainty.
    Mov Disord. 2024 Mar 14. doi: 10.1002/mds.29760.
    PubMed     Abstract available


  295. MENEZES JR, Nunes GA, Carra RB, da Silva Simoes J, et al
    Trans-Spinal Theta Burst Magnetic Stimulation in Parkinson's Disease and Gait Disorders.
    Mov Disord. 2024 Mar 13. doi: 10.1002/mds.29776.
    PubMed     Abstract available


  296. PARDO J, Montal V, Campabadal A, Oltra J, et al
    Cortical Macro- and Microstructural Changes in Parkinson's Disease with Probable Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2024 Mar 8. doi: 10.1002/mds.29761.
    PubMed     Abstract available


  297. SISODIA V, Malekzadeh A, Verwijk E, Schuurman PR, et al
    Bidirectional Interplay between Deep Brain Stimulation and Cognition in Parkinson's Disease: A Systematic Review.
    Mov Disord. 2024 Mar 1. doi: 10.1002/mds.29772.
    PubMed     Abstract available


  298. BINGHAM CS, McIntyre CC
    Coupled Activation of the Hyperdirect and Cerebellothalamic Pathways with Zona Incerta Deep Brain Stimulation.
    Mov Disord. 2024;39:539-545.
    PubMed     Abstract available


  299. LEWITT PA, Stebbins GT, Christensen KV, Tan R, et al
    Buspirone and Zolmitriptan Combination for Dyskinesia: A Randomized, Controlled, Crossover Study.
    Mov Disord. 2024;39:613-618.
    PubMed     Abstract available


  300. THOMSEN M, Marth K, Loens S, Everding J, et al
    Large-Scale Screening: Phenotypic and Mutational Spectrum in Isolated and Combined Dystonia Genes.
    Mov Disord. 2024;39:526-538.
    PubMed     Abstract available


  301. MUNCHAU A, Klein C, Beste C
    Rethinking Movement Disorders.
    Mov Disord. 2024;39:472-484.
    PubMed     Abstract available


  302. KAMATH SD, Holla VV, Phulpagar P, Kamble N, et al
    Clinicogenetic Characterization of Patients with PD and Heterozygous GBA1 Variants in an Indian Cohort.
    Mov Disord. 2024;39:628-630.
    PubMed    


    February 2024
  303. KRUSE C, Lipinski A, Verheyen M, Balzer-Geldsetzer M, et al
    Care of Late-Stage Parkinsonism: Resource Utilization of the Disease in Five European Countries.
    Mov Disord. 2024 Feb 29. doi: 10.1002/mds.29718.
    PubMed     Abstract available


  304. WILKEN M, Andres DS, Bianchi G, Hallett M, et al
    Persistence of Basal Ganglia Oscillatory Activity During Tremor Attenuation by Movement in Parkinson's Disease Patients.
    Mov Disord. 2024 Feb 28. doi: 10.1002/mds.29679.
    PubMed     Abstract available


  305. OJO OO, Bandres-Ciga S, Makarious MB, Crea PW, et al
    GBA1 rs3115534 Is Associated with REM Sleep Behavior Disorder in Parkinson's Disease in Nigerians.
    Mov Disord. 2024 Feb 23. doi: 10.1002/mds.29753.
    PubMed     Abstract available


  306. DORSEY ER, Kinel D, Pawlik ME, Zafar M, et al
    Dry-Cleaning Chemicals and a Cluster of Parkinson's Disease and Cancer: A Retrospective Investigation.
    Mov Disord. 2024 Feb 23. doi: 10.1002/mds.29723.
    PubMed     Abstract available


  307. AMBROSINI E, Cancilla R, Paul JJ, Bauer P, et al
    Pure Parkinsonism as Possible Phenotype Expansion of THAP1-Related Disorders.
    Mov Disord. 2024 Feb 15. doi: 10.1002/mds.29745.
    PubMed    


  308. SOLIS GP, Larasati YA, Thiel M, Koval A, et al
    GNAO1 Mutations Affecting the N-Terminal alpha-Helix of Galphao Lead to Parkinsonism.
    Mov Disord. 2024 Feb 15. doi: 10.1002/mds.29720.
    PubMed     Abstract available


  309. PAPAGIANNAKIS N, Liu H, Koros C, Simitsi AM, et al
    Parkin mRNA Expression Levels in Peripheral Blood Mononuclear Cells in Parkin-Related Parkinson's Disease.
    Mov Disord. 2024 Feb 15. doi: 10.1002/mds.29739.
    PubMed     Abstract available


  310. WEINTRAUB D, Marras C, Amara A, Anderson KE, et al
    Association between Subjective Cognitive Complaints and Incident Functional Impairment in Parkinson's Disease.
    Mov Disord. 2024 Feb 6. doi: 10.1002/mds.29725.
    PubMed     Abstract available


  311. KULCSAROVA K, Skorvanek M
    Challenges and Future of the International Parkinson and Movement Disorder Society Prodromal Parkinson's Disease Criteria: Are We On the Right Track?
    Mov Disord. 2024 Feb 4. doi: 10.1002/mds.29724.
    PubMed    


  312. YUAN X, Wan L, Chen Z, Long Z, et al
    Peripheral Inflammatory and Immune Landscape in Multiple System Atrophy: A Cross-Sectional Study.
    Mov Disord. 2024;39:391-399.
    PubMed     Abstract available


    January 2024
  313. FOLLETT J, Guenther D, Xoi L, Amouri R, et al
    Genetic Modifiers of LRRK2 Parkinson's Disease: A Replication Study in Arab-Berbers.
    Mov Disord. 2024 Jan 31. doi: 10.1002/mds.29735.
    PubMed    


  314. MANGONE G, Tosin MHS, Goetz CG, Stebbins GT, et al
    Unveiling Assessment Gaps in Parkinson's Disease Psychosis: A Scoping Review.
    Mov Disord. 2024 Jan 30. doi: 10.1002/mds.29710.
    PubMed     Abstract available


  315. DAMIER P, Degos B, Castelonovo G, Anheim M, et al
    A Double-Blind, Randomized, Placebo-Controlled Trial of Bumetanide in Parkinson's Disease.
    Mov Disord. 2024 Jan 30. doi: 10.1002/mds.29726.
    PubMed     Abstract available


  316. MARRAS C, Fereshtehnejad SM, Berg D, Bohnen NI, et al
    Transitioning from Subtyping to Precision Medicine in Parkinson's Disease: A Purpose-Driven Approach.
    Mov Disord. 2024 Jan 20. doi: 10.1002/mds.29708.
    PubMed     Abstract available


  317. EIDEM LE, Birkeland E, Austdal M, Bardsen K, et al
    Fatigue in Parkinson's Disease: A Proteomic Study of Cerebrospinal Fluid.
    Mov Disord. 2024 Jan 20. doi: 10.1002/mds.29715.
    PubMed    


  318. DEBOVE I, Paschen S, Amstutz D, Cardoso F, et al
    Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus.
    Mov Disord. 2024 Jan 17. doi: 10.1002/mds.29700.
    PubMed     Abstract available


  319. ROSE KN, Schwarzschild MA, Gomperts SN
    Clearing the Smoke: What Protects Smokers from Parkinson's Disease?
    Mov Disord. 2024 Jan 16. doi: 10.1002/mds.29707.
    PubMed     Abstract available


  320. MULLER S, Kassubek J, Hold ST, Kasper DC, et al
    Morbus Fabry and Parkinson's Disease-More Evidence for a Possible Genetic Link.
    Mov Disord. 2024 Jan 16. doi: 10.1002/mds.29686.
    PubMed    


  321. TUNNICLIFFE L, Weil RS, Breuer J, Rodriguez-Barradas MC, et al
    Herpes Zoster and Risk of Incident Parkinson's Disease in US Veterans: A Matched Cohort Study.
    Mov Disord. 2024 Jan 16. doi: 10.1002/mds.29701.
    PubMed     Abstract available


  322. AMMANN C, Oliviero A, Obeso JA, Foffani G, et al
    Motor Cortex Disinhibition Is Not Associated with Freezing of Gait in Parkinson's Disease.
    Mov Disord. 2024 Jan 5. doi: 10.1002/mds.29709.
    PubMed    


  323. THOMAS GEC, Hannaway N, Zarkali A, Shmueli K, et al
    Longitudinal Associations of Magnetic Susceptibility with Clinical Severity in Parkinson's Disease.
    Mov Disord. 2024 Jan 3. doi: 10.1002/mds.29702.
    PubMed     Abstract available


  324. SICILIANO M, Tessitore A, Morgante F, Goldman JG, et al
    Subjective Cognitive Complaints in Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Mov Disord. 2024 Jan 3. doi: 10.1002/mds.29649.
    PubMed     Abstract available


  325. DOMEN CH, Sillau S, Liu Y, Leehey MA, et al
    Reply to: Cognitive Safety of Cannabis Products in Parkinson's Disease: Need for Solid Scientific Evidence to Guide Clinicians and Patients Currently on Shaky Grounds.
    Mov Disord. 2024;39:222-223.
    PubMed    


  326. GAN-OR Z, Alcalay RN
    Genetics of Parkinson's Disease in Underrepresented Populations: New Studies Pave the Way.
    Mov Disord. 2024;39:1-2.
    PubMed    


  327. BEUDEL M
    Comment on: "A Transatlantic Viewpoint on the Role of Pallidal Stimulation for Parkinson's Disease".
    Mov Disord. 2024;39:223-224.
    PubMed    


  328. SAMPSON TR
    Circulating Extracellular Vesicles as a Potential Mediator of Synuclein Pathology in the Gut.
    Mov Disord. 2024;39:3-5.
    PubMed    


  329. RAU A, Hosp JA, Rijntjes M, Weiller C, et al
    Cerebellar, Not Nigrostriatal Degeneration Impairs Dexterity in Multiple System Atrophy.
    Mov Disord. 2024;39:130-140.
    PubMed     Abstract available


  330. KRISMER F, Peran P, Beliveau V, Seppi K, et al
    Progressive Brain Atrophy in Multiple System Atrophy: A Longitudinal, Multicenter, Magnetic Resonance Imaging Study.
    Mov Disord. 2024;39:119-129.
    PubMed     Abstract available


  331. HILL ME, Johnson LA, Wang J, Escobar Sanabria D, et al
    Paradoxical Modulation of STN beta-Band Activity with Medication Compared to Deep Brain Stimulation.
    Mov Disord. 2024;39:192-197.
    PubMed     Abstract available


    December 2023
  332. MIRELMAN A, Volkov J, Salomon A, Gazit E, et al
    Digital Mobility Measures: A Window into Real-World Severity and Progression of Parkinson's Disease.
    Mov Disord. 2023 Dec 27. doi: 10.1002/mds.29689.
    PubMed     Abstract available


  333. ONG S, Funayama M, Mangyoku Y, Kawai H, et al
    Investigation of 22q11.2 Deletion in Japanese Early-Onset Parkinsonism.
    Mov Disord. 2023 Dec 25. doi: 10.1002/mds.29692.
    PubMed    


  334. JANSSEN DAALEN JM, Koopman WJH, Saris CGJ, Meinders MJ, et al
    The Hypoxia Response Pathway: A Potential Intervention Target in Parkinson's Disease?
    Mov Disord. 2023 Dec 23. doi: 10.1002/mds.29688.
    PubMed     Abstract available


  335. BAIK K, Kim YJ, Park M, Chung SJ, et al
    Functional Brain Networks of Minor and Well-Structured Major Hallucinations in Parkinson's Disease.
    Mov Disord. 2023 Dec 22. doi: 10.1002/mds.29681.
    PubMed     Abstract available


  336. GONZALEZ-ROBLES C, Bartlett M, Burnell M, Clarke CS, et al
    Embedding Patient Input in Outcome Measures for Long-Term Disease-Modifying Parkinson Disease Trials.
    Mov Disord. 2023 Dec 22. doi: 10.1002/mds.29691.
    PubMed     Abstract available


  337. TUNOLD JA, Tan MMX, Toft M, Ross O, et al
    Lysosomal Polygenic Burden Drives Cognitive Decline in Parkinson's Disease with Low Alzheimer Risk.
    Mov Disord. 2023 Dec 20. doi: 10.1002/mds.29698.
    PubMed     Abstract available


  338. ESPAY AJ, Hauser RA, Dhall R, Thakkar S, et al
    Safety and Efficacy of IPX203 in Parkinson's Disease: The RISE-PD Open-Label Extension Study.
    Mov Disord. 2023 Dec 18. doi: 10.1002/mds.29685.
    PubMed     Abstract available


  339. MARANO M, Anzini G, Saltarocchi L, Ricciuti R, et al
    Left Vagus Stimulation Modulates Contralateral Subthalamic beta Power Improving the Gait in Parkinson's Disease.
    Mov Disord. 2023 Dec 18. doi: 10.1002/mds.29690.
    PubMed     Abstract available


  340. CARDOSO F, Goetz CG, Mestre TA, Sampaio C, et al
    A Statement of the MDS on Biological Definition, Staging, and Classification of Parkinson's Disease.
    Mov Disord. 2023 Dec 13. doi: 10.1002/mds.29683.
    PubMed    


  341. MYLIUS V, Baars JH, Witt K, Benninger D, et al
    Deep Brain Stimulation Improves Parkinson's Disease-Associated Pain by Decreasing Spinal Nociception.
    Mov Disord. 2023 Dec 9. doi: 10.1002/mds.29666.
    PubMed     Abstract available


  342. KIM DJ, Isidro-Perez AL, Doering M, Llibre-Rodriguez JJ, et al
    Prevalence and Incidence of Parkinson's Disease in Latin America: A Meta-Analysis.
    Mov Disord. 2023 Dec 8. doi: 10.1002/mds.29682.
    PubMed     Abstract available


  343. BRISSENDEN JA, Scerbak T, Albin RL, Lee TG, et al
    Motivational Vigor in Parkinson's Disease Requires the Short and Long Duration Response to Levodopa.
    Mov Disord. 2023 Dec 7. doi: 10.1002/mds.29659.
    PubMed     Abstract available


  344. FIORENZATO E, Moaveninejad S, Weis L, Biundo R, et al
    Brain Dynamics Complexity as a Signature of Cognitive Decline in Parkinson's Disease.
    Mov Disord. 2023 Dec 6. doi: 10.1002/mds.29678.
    PubMed     Abstract available


  345. MULLER T, Kuhn W
    An Indirect Proof for Levodopa-Induced Vitamin Deficiency in Parkinson's Disease.
    Mov Disord. 2023;38:2319-2320.
    PubMed    


  346. NAMBU A, Chiken S, Sano H, Hatanaka N, et al
    Dynamic Activity Model of Movement Disorders: The Fundamental Role of the Hyperdirect Pathway.
    Mov Disord. 2023;38:2145-2150.
    PubMed     Abstract available


  347. ZHENG Y, Cai H, Wang X, Zhang N, et al
    Erythrocytic alpha-Synuclein Species as Biomarkers for Isolated Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2023;38:2315-2317.
    PubMed    


    November 2023
  348. ANDREWS SV, Kukkle PL, Menon R, Geetha TS, et al
    The Genetic Drivers of Juvenile, Young, and Early-Onset Parkinson's Disease in India.
    Mov Disord. 2023 Nov 28. doi: 10.1002/mds.29676.
    PubMed     Abstract available


  349. WANG J, Li H, Jia J, Shao X, et al
    Progressive Cerebrovascular Reactivity Reduction Occurs in Parkinson's Disease: A Longitudinal Study.
    Mov Disord. 2023 Nov 27. doi: 10.1002/mds.29671.
    PubMed     Abstract available


  350. ONGARI G, Ghezzi C, Di Martino D, Pisani A, et al
    Impaired Mitochondrial Respiration in REM-Sleep Behavior Disorder: A Biomarker of Parkinson's Disease?
    Mov Disord. 2023 Nov 25. doi: 10.1002/mds.29643.
    PubMed     Abstract available


  351. DI FOLCO C, Couronne R, Arnulf I, Mangone G, et al
    Charting Disease Trajectories from Isolated REM Sleep Behavior Disorder to Parkinson's Disease.
    Mov Disord. 2023 Nov 25. doi: 10.1002/mds.29662.
    PubMed     Abstract available



  352. Correction to Excessive alpha-beta Oscillations Mark Enlarged Motor Sign Severity and Parkinson's Disease Duration.
    Mov Disord. 2023 Nov 22. doi: 10.1002/mds.29660.
    PubMed    


  353. MA DR, Li SJ, Shi JJ, Liang YY, et al
    Shared Genetic Architecture between Parkinson's Disease and Brain Structural Phenotypes.
    Mov Disord. 2023 Nov 21. doi: 10.1002/mds.29598.
    PubMed     Abstract available


  354. KIM A, Martinez-Valbuena I, Keith JL, Kovacs GG, et al
    Misfolded alpha-Synuclein Seeding Is Detected in Suspected LRRK2-Parkinson's Disease without Immunohistochemically Detectable alpha-Synuclein Pathology.
    Mov Disord. 2023 Nov 20. doi: 10.1002/mds.29665.
    PubMed    


  355. BOOGERS A, Fasano A
    A Transatlantic Viewpoint on the Role of Pallidal Stimulation for Parkinson's Disease.
    Mov Disord. 2023 Nov 15. doi: 10.1002/mds.29656.
    PubMed    


  356. KERESTES R, Laansma MA, Owens-Walton C, Perry A, et al
    Cerebellar Volume and Disease Staging in Parkinson's Disease: An ENIGMA-PD Study.
    Mov Disord. 2023 Nov 14. doi: 10.1002/mds.29611.
    PubMed     Abstract available


  357. OERTEL WH, Paule E, Hasemann T, Sittig E, et al
    Reduced Gastric Contraction in Rapid-Eye-Movement Sleep Behavior Disorder and De Novo Parkinson's Disease.
    Mov Disord. 2023 Nov 13. doi: 10.1002/mds.29652.
    PubMed     Abstract available


  358. KONERU V, Espay AJ, Cole AJ, Weintraub D, et al
    The Self-Administered Screening Questionnaire for Parkinson's Disease-Associated Psychosis (SASPAP).
    Mov Disord. 2023 Nov 8. doi: 10.1002/mds.29627.
    PubMed     Abstract available


  359. DAIDA K, Funayama M, Billingsley KJ, Malik L, et al
    Long-Read Sequencing Resolves a Complex Structural Variant in PRKN Parkinson's Disease.
    Mov Disord. 2023 Nov 5. doi: 10.1002/mds.29610.
    PubMed     Abstract available


  360. SAFFIE AWAD P, Teixeira-Dos-Santos D, Santos-Lobato BL, Camargos S, et al
    Frequency of Hereditary and GBA1-Related Parkinsonism in Latin America: A Systematic Review and Meta-Analysis.
    Mov Disord. 2023 Nov 3. doi: 10.1002/mds.29614.
    PubMed     Abstract available


  361. PAL GD, Corcos DM, Metman LV, Israel Z, et al
    Cognitive Effects of Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease with GBA1 Pathogenic Variants.
    Mov Disord. 2023 Nov 2. doi: 10.1002/mds.29647.
    PubMed     Abstract available



  362. The Future of Parkinson's Disease: Improving Care & Driving Research.
    Mov Disord. 2023;38 Suppl 2:S1-S21.
    PubMed    


  363. BERGER SL, Seemiller J, Rosenthal LS
    Synuclein Seed Amplification in the Cerebrospinal Fluid: Research and Clinical Implications.
    Mov Disord. 2023;38:1990-1991.
    PubMed    


  364. VASILEVSKAYA A, Martinez-Valbuena I, Anastassiadis C, Taghdiri F, et al
    Misfolded alpha-Synuclein in Cerebrospinal Fluid of Contact Sport Athletes.
    Mov Disord. 2023;38:2125-2131.
    PubMed     Abstract available


  365. DI LUCA DG, Ramirez-Gomez C, Germann J, Santyr B, et al
    Deep Brain Stimulation of the Globus Pallidus Internus and Externus in Multiple System Atrophy.
    Mov Disord. 2023;38:2121-2125.
    PubMed     Abstract available


    October 2023
  366. OLANOW CW, Hauser RA, Burdick DJ, Dhall R, et al
    A Randomized Phase 3 Study Comparing P2B001 to its Components (Low-Dose Extended-Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended-Release Pramipexole in Early Parkinson's Disease.
    Mov Disord. 2023 Oct 27. doi: 10.1002/mds.29642.
    PubMed     Abstract available


  367. PAHWA R, Merola A, Soileau M, Alobaidi A, et al
    Cost-Effectiveness of Carbidopa-Levodopa Enteral Suspension for Advanced Parkinson's Disease in the United States.
    Mov Disord. 2023 Oct 25. doi: 10.1002/mds.29624.
    PubMed     Abstract available


  368. BOUGOU V, Vanhoyland M, Decramer T, Van Hoylandt A, et al
    Active and Passive Cycling Decrease Subthalamic beta Oscillations in Parkinson's Disease.
    Mov Disord. 2023 Oct 20. doi: 10.1002/mds.29632.
    PubMed     Abstract available


  369. CONTI M, Guerra A, Pierantozzi M, Bovenzi R, et al
    Band-Specific Altered Cortical Connectivity in Early Parkinson's Disease and its Clinical Correlates.
    Mov Disord. 2023 Oct 20. doi: 10.1002/mds.29615.
    PubMed     Abstract available


  370. ALBIN R, Grotewold N
    What is the Parkinson Pandemic?
    Mov Disord. 2023 Oct 20. doi: 10.1002/mds.29637.
    PubMed    


  371. WOO KA, Joun JH, Yoon EJ, Lee CY, et al
    Monoaminergic Degeneration and Ocular Motor Abnormalities in De Novo Parkinson's Disease.
    Mov Disord. 2023 Oct 17. doi: 10.1002/mds.29623.
    PubMed     Abstract available


  372. BUSCH JL, Kaplan J, Bahners BH, Roediger J, et al
    Local Field Potentials Predict Motor Performance in Deep Brain Stimulation for Parkinson's Disease.
    Mov Disord. 2023 Oct 12. doi: 10.1002/mds.29626.
    PubMed     Abstract available


  373. SAMUEL N, Ding MYR, Sarica C, Darmani G, et al
    Accelerated Transcranial Ultrasound Neuromodulation in Parkinson's Disease: A Pilot Study.
    Mov Disord. 2023 Oct 9. doi: 10.1002/mds.29622.
    PubMed     Abstract available


  374. YANG Y, Stewart T, Zhang C, Wang P, et al
    Erythrocytic alpha-Synuclein and the Gut Microbiome: Kindling of the Gut-Brain Axis in Parkinson's Disease.
    Mov Disord. 2023 Oct 5. doi: 10.1002/mds.29620.
    PubMed     Abstract available


  375. WAN L, Fu Y, Chen Z, Long Z, et al
    No Correlation between Plasma GPNMB Levels and Multiple System Atrophy in Chinese Cohorts.
    Mov Disord. 2023;38:1956-1961.
    PubMed     Abstract available


  376. HU Y, Ma TC, Alberico SL, Ding Y, et al
    Substantia Nigra Pars Reticulata Projections to the Pedunculopontine Nucleus Modulate Dyskinesia.
    Mov Disord. 2023;38:1850-1860.
    PubMed     Abstract available


  377. GROSSMANN D, Malburg N, Glass H, Weeren V, et al
    Mitochondria-Endoplasmic Reticulum Contact Sites Dynamics and Calcium Homeostasis Are Differentially Disrupted in PINK1-PD or PRKN-PD Neurons.
    Mov Disord. 2023;38:1822-1836.
    PubMed     Abstract available


    September 2023
  378. JANSSEN DAALEN JM, Oosterhof TH, Bloem BR, Darweesh SKL, et al
    Wearables for Parkinson's: Fast-Paced toward Novel Outcome Measures.
    Mov Disord. 2023 Sep 29. doi: 10.1002/mds.29608.
    PubMed    


  379. SATOH R, Weigand SD, Pham NTT, Ali F, et al
    Magnetic Susceptibility in Progressive Supranuclear Palsy Variants, Parkinson's Disease, and Corticobasal Syndrome.
    Mov Disord. 2023 Sep 29. doi: 10.1002/mds.29613.
    PubMed     Abstract available


  380. DI FONZO A, Percetti M, Monfrini E, Palmieri I, et al
    Harmonizing Genetic Testing for Parkinson's Disease: Results of the PARKNET Multicentric Study.
    Mov Disord. 2023 Sep 26. doi: 10.1002/mds.29617.
    PubMed     Abstract available


  381. TOFFOLI M, Schapira AHV, Proukakis C
    Sex Distribution of GBA1 Variants Carriers with Dementia with Lewy Bodies and Parkinson's Disease.
    Mov Disord. 2023 Sep 22. doi: 10.1002/mds.29609.
    PubMed    


  382. NATALE G, Colella M, De Carluccio M, Lelli D, et al
    Astrocyte Responses Influence Local Effects of Whole-Brain Magnetic Stimulation in Parkinsonian Rats.
    Mov Disord. 2023 Sep 12. doi: 10.1002/mds.29599.
    PubMed     Abstract available


  383. ZHAO Y, Ray A, Broberg K, Kippler M, et al
    Prediagnostic Blood Metal Levels and the Risk of Parkinson's Disease: A Large European Prospective Cohort.
    Mov Disord. 2023 Sep 7. doi: 10.1002/mds.29602.
    PubMed     Abstract available


  384. BOOIJ J, Tellier SP, Seibyl J, Vriend C, et al
    Dopamine Transporter Availability in Early Parkinson's Disease is Dependent on Sunlight Exposure.
    Mov Disord. 2023 Sep 5. doi: 10.1002/mds.29597.
    PubMed     Abstract available


  385. MARKAKI I, Paslawski W, Ntetsika T, Engesvik L, et al
    Isolation of L1CAM-Extracellular Vesicles Reveals Signs of Insulin Resistance in Parkinson's Disease.
    Mov Disord. 2023 Sep 5. doi: 10.1002/mds.29601.
    PubMed    



  386. Correction to "Olfactory Neuron Substance P Is Overexpressed in Parkinson's Disease Reflecting Gut Dysfunction".
    Mov Disord. 2023 Sep 5. doi: 10.1002/mds.29600.
    PubMed    


  387. FINK A, Dodel R, Georges D, Doblhammer G, et al
    The Impact of Sex-Specific Survival on the Incidence of Dementia in Parkinson's Disease.
    Mov Disord. 2023 Sep 1. doi: 10.1002/mds.29596.
    PubMed     Abstract available


  388. BOON LI, Buijink AWG
    Parkinsonian Tremor: Shaking in Synchrony.
    Mov Disord. 2023;38:1582-1584.
    PubMed    


  389. GONZALEZ-LATAPI P, Lo RY
    Bone First or Brain First: "Picking at the Bones" of Parkinson's Disease.
    Mov Disord. 2023;38:1579-1581.
    PubMed    


  390. ZHANG D, Zhou L, Yao J, Shi Y, et al
    Increased Free Water in the Putamen in Idiopathic REM Sleep Behavior Disorder.
    Mov Disord. 2023;38:1645-1654.
    PubMed     Abstract available


    August 2023
  391. SUN H, Gan C, Wang L, Ji M, et al
    Cortical Disinhibition Drives Freezing of Gait in Parkinson's Disease and an Exploratory Repetitive Transcranial Magnetic Stimulation Study.
    Mov Disord. 2023 Aug 30. doi: 10.1002/mds.29595.
    PubMed     Abstract available


  392. TOTSUNE T, Baba T, Sugimura Y, Oizumi H, et al
    Nuclear Imaging Data-Driven Classification of Parkinson's Disease.
    Mov Disord. 2023 Aug 28. doi: 10.1002/mds.29582.
    PubMed     Abstract available


  393. WEINTRAUB D
    What's in a Name? The Time Has Come to Unify Parkinson's Disease and Dementia with Lewy Bodies.
    Mov Disord. 2023 Aug 23. doi: 10.1002/mds.29590.
    PubMed    


  394. ANDICA C, Kamagata K, Uchida W, Saito Y, et al
    Fiber-Specific White Matter Alterations in Parkinson's Disease Patients with GBA Gene Mutations.
    Mov Disord. 2023 Aug 22. doi: 10.1002/mds.29578.
    PubMed     Abstract available


  395. PARK KY, Jung JH, Hwang HS, Park HK, et al
    Bone Mineral Density and the Risk of Parkinson's Disease in Postmenopausal Women.
    Mov Disord. 2023 Aug 21. doi: 10.1002/mds.29579.
    PubMed     Abstract available


  396. TRESSERRA-RIMBAU A, Thompson AS, Bondonno N, Jennings A, et al
    Plant-Based Dietary Patterns and Parkinson's Disease: A Prospective Analysis of the UK Biobank.
    Mov Disord. 2023 Aug 21. doi: 10.1002/mds.29580.
    PubMed     Abstract available


  397. DAI L, Wang J, Zhang X, Yan M, et al
    27-Hydroxycholesterol Drives the Spread of alpha-Synuclein Pathology in Parkinson's Disease.
    Mov Disord. 2023 Aug 18. doi: 10.1002/mds.29577.
    PubMed     Abstract available


  398. BAR-ON M, Baharav S, Katzir Z, Mirelman A, et al
    Task-Related Reorganization of Cognitive Network in Parkinson's Disease Using Electrophysiology.
    Mov Disord. 2023 Aug 8. doi: 10.1002/mds.29571.
    PubMed     Abstract available


  399. GAARE JJ, Brugger K, Nido GS, Tzoulis C, et al
    DNA Methylation Age Acceleration Is Not Associated with Age of Onset in Parkinson's Disease.
    Mov Disord. 2023 Aug 7. doi: 10.1002/mds.29574.
    PubMed     Abstract available


  400. CHU Y, Kordower JH
    Post-Mortem Studies of Neurturin Gene Therapy for Parkinson's Disease: Two Subjects with 10 Years CERE120 Delivery.
    Mov Disord. 2023 Aug 6. doi: 10.1002/mds.29518.
    PubMed     Abstract available


  401. TA M, Blauwendraat C, Antar T, Leonard HL, et al
    Genome-Wide Meta-Analysis of Cerebrospinal Fluid Biomarkers in Alzheimer's Disease and Parkinson's Disease Cohorts.
    Mov Disord. 2023 Aug 4. doi: 10.1002/mds.29511.
    PubMed     Abstract available


  402. CHUA MMJ, Blitz SE, Ng PR, Segar DJ, et al
    Focused Ultrasound Thalamotomy for Tremor in Parkinson's Disease: Outcomes in a Large, Prospective Cohort.
    Mov Disord. 2023 Aug 4. doi: 10.1002/mds.29569.
    PubMed     Abstract available


  403. TIAN Y, Ma G, Li H, Zeng Y, et al
    Shared Genetics and Comorbid Genes of Amyotrophic Lateral Sclerosis and Parkinson's Disease.
    Mov Disord. 2023 Aug 3. doi: 10.1002/mds.29572.
    PubMed     Abstract available


  404. AQUINO C, Luo L, Agarwal P, Garg K, et al
    Deep Brain Stimulation as an Exclusion Criteria in Parkinson's Disease Studies: Time to Rethink?
    Mov Disord. 2023 Aug 2. doi: 10.1002/mds.29554.
    PubMed    


  405. VIRAMETEEKUL S, de Pablo-Fernandez E
    Variability in the Accuracy of Clinical Diagnosis of Early Parkinson's Disease.
    Mov Disord. 2023;38:1574-1575.
    PubMed    


  406. GOETZ CG, Zou H, Stebbins GT, Schrag A, et al
    Reply to: Comment on "Summing MDS-UPDRS Parts 1 + 2 (Non-motor and Motor Experience of Daily Living): The Patient's Voice".
    Mov Disord. 2023;38:1564.
    PubMed    


  407. KOVACS N, Aschermann Z, Harmat M, Rohonczi M, et al
    Comment on "Summing MDS-UPDRS Parts 1 + 2 (Nonmotor and Motor Experience of Daily Living): The Patient's Voice".
    Mov Disord. 2023;38:1563-1564.
    PubMed    


  408. BEACH TG, Adler CH, Shill HA, Zhang N, et al
    Accuracy of the Early Diagnosis of Parkinson's Disease.
    Mov Disord. 2023;38:1573-1574.
    PubMed    


  409. KLIETZ M, Mahmoudi N, Maudsley AA, Sheriff S, et al
    Whole-Brain Magnetic Resonance Spectroscopy Reveals Distinct Alterations in Neurometabolic Profile in Progressive Supranuclear Palsy.
    Mov Disord. 2023;38:1503-1514.
    PubMed     Abstract available


  410. AGIN-LIEBES J, Hickman RA, Vonsattel JP, Faust PL, et al
    Patterns of TDP-43 Deposition in Brains with LRRK2 G2019S Mutations.
    Mov Disord. 2023;38:1541-1545.
    PubMed     Abstract available



  411. Abstracts of the 2023 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2023;38 Suppl 1:S1-S871.
    PubMed    


  412. ALBANESE A, Bhatia KP, Cardoso F, Comella C, et al
    Isolated Cervical Dystonia: Diagnosis and Classification.
    Mov Disord. 2023;38:1367-1378.
    PubMed     Abstract available


    July 2023
  413. LABRADOR-ESPINOSA MA, Silva-Rodriguez J, Reina-Castillo MI, Mir P, et al
    Basal Forebrain Atrophy, Cortical Thinning, and Amyloid-beta Status in Parkinson's disease-Related Cognitive Decline.
    Mov Disord. 2023 Jul 26. doi: 10.1002/mds.29564.
    PubMed     Abstract available


  414. BORSCHE M, Berg D
    Blood-Based alpha-Synuclein Seeding-A New Era for Identifying Parkinsonian Syndromes.
    Mov Disord. 2023 Jul 25. doi: 10.1002/mds.29555.
    PubMed    


  415. JEONG SH, Kim SH, Park CW, Lee HS, et al
    Differential Implications of Cerebral Hypoperfusion and Hyperperfusion in Parkinson's Disease.
    Mov Disord. 2023 Jul 25. doi: 10.1002/mds.29565.
    PubMed     Abstract available


  416. LUTH T, Gabbert C, Koch S, Konig IR, et al
    Interaction of Mitochondrial Polygenic Score and Lifestyle Factors in LRRK2 p.Gly2019Ser Parkinsonism.
    Mov Disord. 2023 Jul 21. doi: 10.1002/mds.29563.
    PubMed     Abstract available


  417. LEAL TP, Rao SC, French-Kwawu JN, Gouveia MH, et al
    X-Chromosome Association Study in Latin American Cohorts Identifies New Loci in Parkinson's Disease.
    Mov Disord. 2023 Jul 20. doi: 10.1002/mds.29508.
    PubMed     Abstract available


  418. XYLAKI M, Chopra A, Weber S, Bartl M, et al
    Extracellular Vesicles for the Diagnosis of Parkinson's Disease: Systematic Review and Meta-Analysis.
    Mov Disord. 2023 Jul 14. doi: 10.1002/mds.29497.
    PubMed     Abstract available


  419. TESSON C, Bouchetara MS, Ferrien M, Lesage S, et al
    Identification of a DAGLB Mutation in a Non-Chinese Patient with Parkinson's Disease.
    Mov Disord. 2023 Jul 11. doi: 10.1002/mds.29533.
    PubMed    


  420. ZHUPARRIS A, Thijssen E, Elzinga WO, Makai-Boloni S, et al
    Treatment Detection and Movement Disorder Society-Unified Parkinson's Disease Rating Scale, Part III Estimation Using Finger Tapping Tasks.
    Mov Disord. 2023 Jul 4. doi: 10.1002/mds.29520.
    PubMed     Abstract available


  421. ARSHAD U, Rahman F, Hanan N, Chen C, et al
    Longitudinal Meta-Analysis of Historical Parkinson's Disease Trials to Inform Future Trial Design.
    Mov Disord. 2023 Jul 3. doi: 10.1002/mds.29514.
    PubMed     Abstract available


  422. TURNER TH, Hinson VK
    Cognitive Safety of Cannabis Products in Parkinson's Disease: Need for Solid Scientific Evidence to Guide Clinicians and Patients Currently on Shaky Grounds.
    Mov Disord. 2023;38:1125-1126.
    PubMed    


  423. PU J, Lin L, Jiang H, Hu Z, et al
    Parkin Maintains Robust Pacemaking in Human Induced Pluripotent Stem Cell-Derived A9 Dopaminergic Neurons.
    Mov Disord. 2023;38:1273-1281.
    PubMed     Abstract available


  424. ZOU H, Goetz CG, Stebbins GT, Schrag A, et al
    Summing MDS-UPDRS Parts 1 + 2 (Non-motor and Motor Experience of Daily Living): The Patient's Voice.
    Mov Disord. 2023;38:1363-1364.
    PubMed    


    June 2023
  425. SCHLIESSER P, Struebing FL, Northoff BH, Kurz A, et al
    Detection of a Parkinson's Disease-Specific MicroRNA Signature in Nasal and Oral Swabs.
    Mov Disord. 2023 Jun 29. doi: 10.1002/mds.29515.
    PubMed     Abstract available


  426. VON BELOW D, Wallerstedt SM, Bergquist F
    Validation of the Swedish Patient-Reported Outcomes in Parkinson's Disease Scale in Outpatients.
    Mov Disord. 2023 Jun 29. doi: 10.1002/mds.29517.
    PubMed     Abstract available


  427. SENKEVICH K, Beletskaia M, Dworkind A, Yu E, et al
    Association of Rare Variants in ARSA with Parkinson's Disease.
    Mov Disord. 2023 Jun 28. doi: 10.1002/mds.29521.
    PubMed     Abstract available


  428. PAL G, Cook L, Schulze J, Verbrugge J, et al
    Genetic Testing in Parkinson's Disease.
    Mov Disord. 2023 Jun 27. doi: 10.1002/mds.29500.
    PubMed     Abstract available


  429. DIRKX MF, Shine JM, Helmich RC
    Integrative Brain States Facilitate the Expression of Parkinson's Tremor.
    Mov Disord. 2023 Jun 26. doi: 10.1002/mds.29506.
    PubMed     Abstract available


  430. VENUTO CS, Smith G, Herbst K, Zielinski R, et al
    Predicting Ambulatory Capacity in Parkinson's Disease to Analyze Progression, Biomarkers, and Trial Design.
    Mov Disord. 2023 Jun 26. doi: 10.1002/mds.29519.
    PubMed     Abstract available


  431. LIN CP, Knoop LEJ, Frigerio I, Bol JGJM, et al
    Nigral Pathology Contributes to Microstructural Integrity of Striatal and Frontal Tracts in Parkinson's Disease.
    Mov Disord. 2023 Jun 22. doi: 10.1002/mds.29510.
    PubMed     Abstract available


  432. SICILIANO M, De Micco R, Russo AG, Esposito F, et al
    Memory Phenotypes In Early, De Novo Parkinson's Disease Patients with Mild Cognitive Impairment.
    Mov Disord. 2023 Jun 15. doi: 10.1002/mds.29502.
    PubMed     Abstract available


  433. HAMEDANI AG, Auinger P, Willis AW, Safarpour D, et al
    Adjusting for Underrepresentation Reveals Widespread Underestimation of Parkinson's Disease Symptom Burden.
    Mov Disord. 2023 Jun 15. doi: 10.1002/mds.29507.
    PubMed     Abstract available


  434. SIMONET C, Mahlknecht P, Marini K, Seppi K, et al
    The Emergence and Progression of Motor Dysfunction in Individuals at Risk of Parkinson's Disease.
    Mov Disord. 2023 Jun 15. doi: 10.1002/mds.29496.
    PubMed     Abstract available


  435. FLORES-TORRES MH, Bjornevik K, Hung AY, Healy BC, et al
    Subjective Cognitive Decline in Women with Features Suggestive of Prodromal Parkinson's Disease.
    Mov Disord. 2023 Jun 14. doi: 10.1002/mds.29503.
    PubMed     Abstract available


  436. YASSINE S, Gschwandtner U, Auffret M, Duprez J, et al
    Identification of Parkinson's Disease Subtypes from Resting-State Electroencephalography.
    Mov Disord. 2023 Jun 13. doi: 10.1002/mds.29451.
    PubMed     Abstract available


  437. SAUNDERS-PULLMAN R, Raymond D, Ortega RA, Shalash A, et al
    International Genetic Testing and Counseling Practices for Parkinson's Disease.
    Mov Disord. 2023 Jun 13. doi: 10.1002/mds.29442.
    PubMed     Abstract available


  438. SCOTT GD, Neilson LE, Woltjer R, Quinn JF, et al
    Lifelong Association of Disorders Related to Military Trauma with Subsequent Parkinson's Disease.
    Mov Disord. 2023 Jun 13. doi: 10.1002/mds.29457.
    PubMed     Abstract available


  439. GILES DORAN C, Wilson F, Goulding SR, Mazzocchi M, et al
    Bioinformatics and Immunohistochemical Analyses Support Preserved Expression of Glial Cell Line-Derived Neurotrophic Factor Receptor RET in Parkinson's.
    Mov Disord. 2023;38:1115-1116.
    PubMed    


  440. WHONE A
    Reply to: "Bioinformatics and Immunohistochemistry Show Preserved Expression of GDNF Receptor RET in Parkinson's".
    Mov Disord. 2023;38:1117-1118.
    PubMed    


  441. PAL GD, David FJ, Shils JL, Munoz MJ, et al
    Subthalamic Physiology in Genetic Subtypes of Parkinson's Disease.
    Mov Disord. 2023;38:1113-1114.
    PubMed    


  442. WEILL C, Gallant A, Baker Erdman H, Abu Snineh M, et al
    Reply to: "Subthalamic Physiology in Genetic Subtypes of Parkinson's Disease".
    Mov Disord. 2023;38:1114.
    PubMed    


  443. NEUMANN WJ, Gilron R, Little S, Tinkhauser G, et al
    Adaptive Deep Brain Stimulation: From Experimental Evidence Toward Practical Implementation.
    Mov Disord. 2023;38:937-948.
    PubMed     Abstract available


  444. MARTINO D, Karnik V, Bhidayasiri R, Hall DA, et al
    Scales for Antipsychotic-Associated Movement Disorders: Systematic Review, Critique, and Recommendations.
    Mov Disord. 2023;38:1008-1026.
    PubMed     Abstract available


  445. SCHIDLITZKI A, Stanojlovic M, Fournier C, Kaufer C, et al
    Double-Edged Effects of Venglustat on Behavior and Pathology in Mice Overexpressing alpha-Synuclein.
    Mov Disord. 2023;38:1044-1055.
    PubMed     Abstract available


  446. STEFANI A, Serradell M, Holzknecht E, Gaig C, et al
    Low Specificity of Rapid Eye Movement Sleep Behavior Disorder Questionnaires: Need for Better Screening Methods.
    Mov Disord. 2023;38:1000-1007.
    PubMed     Abstract available


  447. UEDA J, Uemura N, Ishimoto T, Taguchi T, et al
    Ca(2+) -Calmodulin-Calcineurin Signaling Modulates alpha-Synuclein Transmission.
    Mov Disord. 2023;38:1056-1067.
    PubMed     Abstract available


  448. PEREZ-CARBONELL L, Simonet C, Chohan H, Gill A, et al
    The Views of Patients with Isolated Rapid Eye Movement Sleep Behavior Disorder on Risk Disclosure.
    Mov Disord. 2023;38:1089-1093.
    PubMed     Abstract available


  449. KUZKINA A, Panzer C, Seger A, Schmitt D, et al
    Dermal Real-Time Quaking-Induced Conversion Is a Sensitive Marker to Confirm Isolated Rapid Eye Movement Sleep Behavior Disorder as an Early alpha-Synucleinopathy.
    Mov Disord. 2023;38:1077-1082.
    PubMed     Abstract available


    May 2023
  450. PAYNE T, Appleby M, Buckley E, van Gelder LMA, et al
    A Double-Blind, Randomized, Placebo-Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease.
    Mov Disord. 2023 May 29. doi: 10.1002/mds.29450.
    PubMed     Abstract available


  451. GEORGIADES MJ, Shine JM, Gilat M, McMaster J, et al
    Subthalamic Nucleus Activity during Cognitive Load and Gait Dysfunction in Parkinson's Disease.
    Mov Disord. 2023 May 25. doi: 10.1002/mds.29455.
    PubMed     Abstract available


  452. DOMEN CH, Sillau S, Liu Y, Adkins M, et al
    Cognitive Safety Data from a Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase IIb Study of the Effects of a Cannabidiol and Delta9-Tetrahydrocannabinol Drug on Parkinson's Disease-Related Motor Symptoms.
    Mov Disord. 2023 May 22. doi: 10.1002/mds.29447.
    PubMed     Abstract available


  453. HUTTUNEN HJ, Booms S, Sjogren M, Kerstens V, et al
    Intraputamenal Cerebral Dopamine Neurotrophic Factor in Parkinson's Disease: A Randomized, Double-Blind, Multicenter Phase 1 Trial.
    Mov Disord. 2023 May 22. doi: 10.1002/mds.29426.
    PubMed     Abstract available


  454. KROSCHE M, Kannenberg S, Butz M, Hartmann CJ, et al
    Slowing of Frontal beta Oscillations in Atypical Parkinsonism.
    Mov Disord. 2023 May 20. doi: 10.1002/mds.29378.
    PubMed     Abstract available


  455. DEN HEIJER JM, Kruithof AC, Moerland M, Walker M, et al
    A Phase 1B Trial in GBA1-Associated Parkinson's Disease of BIA-28-6156, a Glucocerebrosidase Activator.
    Mov Disord. 2023 May 17. doi: 10.1002/mds.29346.
    PubMed     Abstract available


  456. RAFEE S, Fearon C
    Palmitoylation: A New Therapeutic Target for Parkinson's Disease?
    Mov Disord. 2023 May 11. doi: 10.1002/mds.29418.
    PubMed    


  457. MAMARIL-DAVIS JC, Gelb AW, Larson PS
    Procedure-Related Complications in Sham Surgeries for Parkinson's Clinical Trials: A Meta-analysis.
    Mov Disord. 2023 May 11. doi: 10.1002/mds.29406.
    PubMed     Abstract available


  458. SCHIRINZI T, Maftei D, Grillo P, Bovenzi R, et al
    Olfactory Neuron Substance P is Overexpressed in Parkinson's Disease Reflecting Gut Dysfunction.
    Mov Disord. 2023 May 8. doi: 10.1002/mds.29433.
    PubMed    


  459. BROWN GC, Camacho M, Williams-Gray CH
    The Endotoxin Hypothesis of Parkinson's Disease.
    Mov Disord. 2023 May 8. doi: 10.1002/mds.29432.
    PubMed     Abstract available


  460. RYMAN SG, Shaff N, Dodd A, Nitschke S, et al
    Reduced and Delayed Cerebrovascular Reactivity in Patients with Parkinson's Disease.
    Mov Disord. 2023 May 8. doi: 10.1002/mds.29429.
    PubMed     Abstract available


  461. OUTEIRO TF, Alcalay RN, Antonini A, Attems J, et al
    Defining the Riddle in Order to Solve It: There Is More Than One "Parkinson's Disease".
    Mov Disord. 2023 May 8. doi: 10.1002/mds.29419.
    PubMed     Abstract available


  462. KOROS C, Brockmann K, Simitsi AM, Bougea A, et al
    Impact of APOE Genotype on Cognition in Idiopathic and Genetic Forms of Parkinson's Disease.
    Mov Disord. 2023 May 6. doi: 10.1002/mds.29399.
    PubMed    


  463. SENKEVICH K, Alipour P, Chernyavskaya E, Yu E, et al
    Potential Protective Link Between Type I Diabetes and Parkinson's Disease Risk and Progression.
    Mov Disord. 2023 May 6. doi: 10.1002/mds.29424.
    PubMed     Abstract available


  464. VALENTIJN PP, Eggers C, Bloem BR, Grimes D, et al
    Validation of the Rainbow Model of Integrated Care Measurement Tool in Parkinson's Disease.
    Mov Disord. 2023 May 6. doi: 10.1002/mds.29413.
    PubMed     Abstract available


  465. NG J, Barral S, Waddington SN, Kurian MA, et al
    Gene Therapy for Dopamine Dyshomeostasis: From Parkinson's to Primary Neurotransmitter Diseases.
    Mov Disord. 2023 May 5. doi: 10.1002/mds.29416.
    PubMed     Abstract available


  466. JOST ST, Kaldenbach MA, Antonini A, Martinez-Martin P, et al
    Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals.
    Mov Disord. 2023 May 5. doi: 10.1002/mds.29410.
    PubMed     Abstract available


  467. AVERNA A, Debove I, Nowacki A, Peterman K, et al
    Spectral Topography of the Subthalamic Nucleus to Inform Next-Generation Deep Brain Stimulation.
    Mov Disord. 2023;38:818-830.
    PubMed     Abstract available


  468. LOFREDI R, Scheller U, Mindermann A, Feldmann LK, et al
    Pallidal Beta Activity Is Linked to Stimulation-Induced Slowness in Dystonia.
    Mov Disord. 2023;38:894-899.
    PubMed     Abstract available


  469. ZHANG D, Shi Y, Yao J, Zhou L, et al
    Free-Water Imaging of the Substantia Nigra in GBA Pathogenic Variant Carriers.
    Mov Disord. 2023;38:764-773.
    PubMed     Abstract available


    April 2023
  470. MESTRE TA, McDermott MP, Lobo R, Ferreira JJ, et al
    The Lessebo Effect in Disease Modification Trials in Parkinson's Disease.
    Mov Disord. 2023 Apr 24. doi: 10.1002/mds.29414.
    PubMed     Abstract available


  471. GEROIN C, Artusi CA, Nonnekes J, Aquino C, et al
    Axial Postural Abnormalities in Parkinsonism: Gaps in Predictors, Pathophysiology, and Management.
    Mov Disord. 2023 Apr 20. doi: 10.1002/mds.29377.
    PubMed    


  472. LI C, Lin J, Jiang Q, Yang T, et al
    Cross-Ethnic Variant Screening and Burden Analysis of PTPA in Parkinson's Disease.
    Mov Disord. 2023 Apr 12. doi: 10.1002/mds.29411.
    PubMed     Abstract available


  473. OH YS, Kim JS, Lyoo CH, Kim H, et al
    Obstructive Sleep Apnea and Striatal Dopamine Availability in Parkinson's Disease.
    Mov Disord. 2023 Apr 12. doi: 10.1002/mds.29402.
    PubMed     Abstract available


  474. BELOVA E, Semenova U, Gamaleya A, Tomskiy A, et al
    Excessive alpha-beta Oscillations Mark Enlarged Motor Sign Severity and Parkinson's Disease Duration.
    Mov Disord. 2023 Apr 6. doi: 10.1002/mds.29393.
    PubMed     Abstract available


  475. MULLER T, Kuhn W
    Epigenetic Drug Effects in Levodopa-Treated Patients with Parkinson's Disease.
    Mov Disord. 2023;38:710-711.
    PubMed    


  476. THALER A, Mirelman A, Alcalay RN
    Differences in Sex-Specific Frequency of Glucocerebrosidase Variant Carriers and Familial Parkinsonism.
    Mov Disord. 2023;38:713-714.
    PubMed    


  477. YANG X, Xiao Q
    Reply to: "Epigenetic Drug Effects in Levodopa Treated Patients with Parkinson's Disease".
    Mov Disord. 2023;38:711.
    PubMed    


  478. LANG AE
    Targeting alpha-Synuclein: A Further Viewpoint.
    Mov Disord. 2023;38:715-716.
    PubMed    


  479. POSTUMA RB, Lang AE
    The Clinical Diagnosis of Parkinson's Disease-We Are Getting Better.
    Mov Disord. 2023;38:515-517.
    PubMed    


  480. ORTEGA RA, Bressman SB, Raymond D, Ozelius LJ, et al
    Differences in Sex-Specific Frequency of Glucocerebrosidase Variant Carriers and Familial Parkinsonism.
    Mov Disord. 2023;38:714-715.
    PubMed    


  481. PERCETTI M, Monfrini E, Caporali L, Minardi R, et al
    Reply to: "Lack of Association between TWNK Rare Variants and Parkinson's Disease in a Chinese Cohort".
    Mov Disord. 2023;38:709-710.
    PubMed    


  482. KRESOJEVIC N, Markovic V, Dobricic V, Stankovic I, et al
    Reply to: "Differences in Sex-Specific Frequency of Glucocerebrosidase Variant Carriers and Familial Parkinsonism".
    Mov Disord. 2023;38:712-713.
    PubMed    


  483. LI C, Lin J, Jiang Q, Yang T, et al
    Lack of Association between TWNK Rare Variants and Parkinson's Disease in a Chinese Cohort.
    Mov Disord. 2023;38:708-709.
    PubMed    


  484. BOLOGNA M, Espay AJ, Fasano A, Paparella G, et al
    Redefining Bradykinesia.
    Mov Disord. 2023;38:551-557.
    PubMed    


  485. HUANG SY, Chen SF, Cui M, Zhao M, et al
    Plasma Biomarkers and Positron Emission Tomography Tau Pathology in Progressive Supranuclear Palsy.
    Mov Disord. 2023;38:676-682.
    PubMed     Abstract available


    March 2023
  486. BORSCHE M, Pratuseviciute N, Schaake S, Hinrichs F, et al
    The New p.F1700L LRRK2 Variant Causes Parkinson's Disease by Extensively Increasing Kinase Activity.
    Mov Disord. 2023 Mar 27. doi: 10.1002/mds.29385.
    PubMed    


  487. ZENG R, Wang J, Zheng C, Jiang R, et al
    Lack of Causal Associations of Inflammatory Bowel Disease with Parkinson's Disease and Other Neurodegenerative Disorders.
    Mov Disord. 2023 Mar 23. doi: 10.1002/mds.29386.
    PubMed     Abstract available


  488. ZHOU G, Ren J, Rong D, Zhou H, et al
    Monitoring Substantia Nigra Degeneration Using Free Water Imaging across Prodromal and Clinical Parkinson's Disease.
    Mov Disord. 2023 Mar 22. doi: 10.1002/mds.29366.
    PubMed     Abstract available


  489. MESTRE TA, Schlossmacher MG
    Target-Specific Strategies to Modify the Course of Parkinson's: Is Iron Chelation Safe?
    Mov Disord. 2023 Mar 21. doi: 10.1002/mds.29382.
    PubMed    


  490. FLORES-TORRES MH, Christine CW, Bjornevik K, Molsberry SA, et al
    Long-Term Intake of Folate, Vitamin B6, and Vitamin B12 and the Incidence of Parkinson's Disease in a Sample of U.S. Women and Men.
    Mov Disord. 2023 Mar 20. doi: 10.1002/mds.29383.
    PubMed     Abstract available


  491. DEN HEIJER JM, Cullen VC, Pereira DR, Yavuz Y, et al
    A Biomarker Study in Patients with GBA1-Parkinson's Disease and Healthy Controls.
    Mov Disord. 2023 Mar 14. doi: 10.1002/mds.29360.
    PubMed     Abstract available


  492. MUNOZ-DELGADO L, Labrador-Espinosa MA, Macias-Garcia D, Jesus S, et al
    Peripheral Inflammation Is Associated with Dopaminergic Degeneration in Parkinson's Disease.
    Mov Disord. 2023 Mar 13. doi: 10.1002/mds.29369.
    PubMed     Abstract available


  493. KAMATH T, Macosko EZ
    Insights into Neurodegeneration in Parkinson's Disease from Single-Cell and Spatial Genomics.
    Mov Disord. 2023 Mar 7. doi: 10.1002/mds.29374.
    PubMed     Abstract available


  494. DORSEY ER, Ray A
    Paraquat, Parkinson's Disease, and Agnotology.
    Mov Disord. 2023 Mar 6. doi: 10.1002/mds.29371.
    PubMed    


  495. BLAUWENDRAAT C, Tayebi N, Woo EG, Lopez G, et al
    Polygenic Parkinson's Disease Genetic Risk Score as Risk Modifier of Parkinsonism in Gaucher Disease.
    Mov Disord. 2023 Mar 3. doi: 10.1002/mds.29342.
    PubMed     Abstract available


  496. MARSILI L, Duque KR, Gregor N, Abdelghany E, et al
    Bradykinesia in Neurodegenerative Disorders: A Blinded Video Analysis of Pathology-Proven Cases.
    Mov Disord. 2023;38:496-501.
    PubMed     Abstract available


  497. JENSEN PH, Schlossmacher MG, Stefanis L
    Who Ever Said It Would Be Easy? Reflecting on Two Clinical Trials Targeting alpha-Synuclein.
    Mov Disord. 2023;38:378-384.
    PubMed     Abstract available


  498. VIRAMETEEKUL S, Revesz T, Jaunmuktane Z, Warner TT, et al
    Pathological Validation of the MDS Criteria for the Diagnosis of Multiple System Atrophy.
    Mov Disord. 2023;38:444-452.
    PubMed     Abstract available


  499. WANG EW, Brown GL, Lewis MM, Jellen LC, et al
    Susceptibility Magnetic Resonance Imaging Correlates with Glial Density and Tau in the Substantia Nigra Pars Compacta.
    Mov Disord. 2023;38:464-473.
    PubMed     Abstract available


  500. TAN C, Nawaz H, Lageman SK, Cloud LJ, et al
    Cholinergic Nucleus 4 Degeneration and Cognitive Impairment in Isolated Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2023;38:474-479.
    PubMed     Abstract available


  501. WIEST C, Morgante F, Torrecillos F, Pogosyan A, et al
    Subthalamic Nucleus Stimulation-Induced Local Field Potential Changes in Dystonia.
    Mov Disord. 2023;38:423-434.
    PubMed     Abstract available


  502. ROSSI M, Hamed M, Rodriguez-Antiguedad J, Cornejo-Olivas M, et al
    Genotype-Phenotype Correlations for ATX-TBP (SCA17): MDSGene Systematic Review.
    Mov Disord. 2023;38:368-377.
    PubMed     Abstract available


    February 2023
  503. YACOUBIAN TA, Fang YD, Gerstenecker A, Amara A, et al
    Brain and Systemic Inflammation in De Novo Parkinson's Disease.
    Mov Disord. 2023 Feb 28. doi: 10.1002/mds.29363.
    PubMed     Abstract available


  504. EMMI A, Sandre M, Russo FP, Tombesi G, et al
    Duodenal alpha-Synuclein Pathology and Enteric Gliosis in Advanced Parkinson's Disease.
    Mov Disord. 2023 Feb 27. doi: 10.1002/mds.29358.
    PubMed     Abstract available


  505. SCIACCA G, Mostile G, Disilvestro I, Donzuso G, et al
    Long-Duration Response to Levodopa, Motor Learning, and Neuroplasticity in Early Parkinson's Disease.
    Mov Disord. 2023 Feb 25. doi: 10.1002/mds.29344.
    PubMed     Abstract available


  506. GOETZ CG, Choi D, Guo Y, Stebbins GT, et al
    It Is as It Was: MDS-UPDRS Part III Scores Cannot Be Combined with Other Parts to Give a Valid Sum.
    Mov Disord. 2023;38:342-347.
    PubMed     Abstract available


  507. GARRIDO A, Fairfoul G, Tolosa E, Marti MJ, et al
    Brain and Cerebrospinal Fluid alpha-Synuclein Real-Time Quaking-Induced Conversion Identifies Lewy Body Pathology in LRRK2-PD.
    Mov Disord. 2023;38:333-338.
    PubMed     Abstract available


  508. OLSEN AL, Clemens SG, Feany MB
    Nicotine-Mediated Rescue of alpha-Synuclein Toxicity Requires Synaptic Vesicle Glycoprotein 2 in Drosophila.
    Mov Disord. 2023;38:244-255.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.